var title_f31_23_32112="Color flow Doppler severe MR";
var content_f31_23_32112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Color flow Doppler of severe mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The color flow Doppler signal, as seen in the four chamber view, shows the typical features of severe mitral regurgitation; the first is a large proximal isovelocity surface area (PISA) and the second is a broad crossing jet from left ventricle (LV) into the left atrium (LA).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_23_32112=[""].join("\n");
var outline_f31_23_32112=null;
var title_f31_23_32113="Appendiceal mucocele Endosc";
var content_f31_23_32113=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Appendiceal mucocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Glossy, rounded, protruding mass arising from appendiceal orifice, consistent with mucocele.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Louis-Michel Wong Kee Song, MD, FRCP and Norman E Marcon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_23_32113=[""].join("\n");
var outline_f31_23_32113=null;
var title_f31_23_32114="Food-borne diseases I";
var content_f31_23_32114=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77956%7EPEDS%2F53848%7EPEDS%2F62562%7EPEDS%2F75804%7EPEDS%2F55831%7EPEDS%2F68671%7EPEDS%2F77344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=29\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77956%7EPEDS%2F53848%7EPEDS%2F62562%7EPEDS%2F75804%7EPEDS%2F55831%7EPEDS%2F68671%7EPEDS%2F77344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=29\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for confirmation of food-borne disease outbreaks-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiologic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        <em>",
"         Bacillus",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Vomiting toxin",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        1-6 hrs",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Vomiting, some patients with diarrhea; fever uncommon",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of organism from stool of two or more ill persons and not from stool of controls",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Isolation of &ge;10",
"        <sup>",
"         5",
"        </sup>",
"        organisms/g from epidemiologically implicated food, provided specimen properly handled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Diarrheal toxin",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        6-24 hrs",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Diarrhea, abdominal cramps, and vomiting in some patients; fever uncommon",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of organism from stool of two or more ill persons and not from stool of controls",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Isolation of &ge;10",
"        <sup>",
"         5",
"        </sup>",
"        organisms/g from epidemiologically implicated food, provided specimen properly handled",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        <em>",
"         Brucella",
"        </em>",
"       </td>",
"       <td>",
"        Several days to several months usually &gt;30 days",
"       </td>",
"       <td>",
"        Weakness, fever, headache, sweats, chills, arthralgia, weight loss, splenomegaly",
"       </td>",
"       <td>",
"        Two or more ill persons and isolation of organism in culture of blood or bone marrow, greater than fourfold increase in standard agglutination titer (SAT) over several wks, or single SAT titer &ge;1:160 in person who has compatible clinical symptoms and history of exposure",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Campylobacter",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        2-10 days, usually 2-5 days",
"       </td>",
"       <td rowspan=\"3\">",
"        Diarrhea (often bloody), abdominal pain, fever",
"       </td>",
"       <td>",
"        Isolation of organism from clinical specimens from two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolation of organism from epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Clostridium botulinum",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        2 hrs-8 days, usually 12-48 hours",
"       </td>",
"       <td rowspan=\"3\">",
"        Illness of variable severity; common symptoms are diplopia, blurred vision, and bulbar weakness; paralysis, which is usually descending and bilateral, may progress rapidly",
"       </td>",
"       <td>",
"        Detection of botulinal toxin in serum, stool, gastric contents, or implicated food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolation of organism from stool or intestine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.cdc.gov/mmwr//mmwr.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for confirmation of food-borne disease outbreaks-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiologic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Bacterial (cont.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Clostridium perfringens",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        6-24 hrs",
"       </td>",
"       <td rowspan=\"3\">",
"        Diarrhea, abdominal cramps; vomiting and fever are uncommon",
"       </td>",
"       <td>",
"        Isolation of &ge;10",
"        <sup>",
"         6",
"        </sup>",
"        organisms/g in stool of two or more ill persons, provided specimen properly handled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demonstration of enterotoxin in the stool of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        <em>",
"         Escherichia coli",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Enterohemorrhagic (EHEC -",
"        <em>",
"         E. coli",
"        </em>",
"        0157:H7 and others)",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        1-10 days, usually 3-4 days",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Diarrhea (often bloody), abdominal cramps (often severe), little or no fever",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of",
"        <em>",
"         E. coli",
"        </em>",
"        O157:H7 or other Shiga toxin-producing",
"        <em>",
"         E. coli",
"        </em>",
"        from clinical specimen of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Isolation of",
"        <em>",
"         E. coli",
"        </em>",
"        O157 or other Shiga toxin-producing",
"        <em>",
"         E. coli",
"        </em>",
"        from epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Enterotoxigenic (ETEC)",
"       </td>",
"       <td class=\"sublist_other\">",
"        6-48 hrs",
"       </td>",
"       <td class=\"sublist_other\">",
"        Diarrhea, abdominal cramps, nausea; vomiting and fever are less common",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of organism of same serotype, which are demonstrated to produce heat-stable (ST) and/or heat-liable (LT) enterotoxin, from stool of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Enteropathogenic (EPEC)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Variable",
"       </td>",
"       <td class=\"sublist_other\">",
"        Diarrhea, fever, abdominal cramps",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of same enteropathogenic serotype from stool of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Enteroinvasive variable (EIEC)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Variable",
"       </td>",
"       <td class=\"sublist_other\">",
"        Diarrhea (may be bloody), fever, abdominal cramps",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of same enteroinvasive serotype from stool of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        <em>",
"         Listeria monocytogenes",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Invasive disease",
"       </td>",
"       <td class=\"sublist_other\">",
"        2-6 weeks",
"       </td>",
"       <td class=\"sublist_other\">",
"        Meningitis, neonatal sepsis, fever",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of organism from normally sterile site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Diarrheal disease",
"       </td>",
"       <td class=\"sublist_other\">",
"        Unknown",
"       </td>",
"       <td class=\"sublist_other\">",
"        Diarrhea, abdominal cramps, fever",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of organism of same serotype from stool of two or more ill persons exposed to food that is epidemiologically implicated or from which organism of same serotype has been isolated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.cdc.gov/mmwr//mmwr.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for confirmation of food-borne disease outbreaks-III",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiologic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Bacterial (cont.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Nontyphoidal",
"        <em>",
"         Salmonella",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        6 hrs-10 days, usually 6-48 hours",
"       </td>",
"       <td rowspan=\"3\">",
"        Diarrhea, often with fever and abdominal cramps",
"       </td>",
"       <td>",
"        Isolation of organism of same serotype from clinical specimens from two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolation of organism from epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Salmonella",
"        </em>",
"        typhi",
"       </td>",
"       <td rowspan=\"3\">",
"        3-60 days, usually 7-14 days",
"       </td>",
"       <td rowspan=\"3\">",
"        Fever, anorexia, malaise, headache, and myalgia; sometimes diarrhea or constipation",
"       </td>",
"       <td>",
"        Isolation of organism from clinical specimens or two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolation of organism from epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Shigella",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        12 hrs-6 days, usually 2-4 days",
"       </td>",
"       <td rowspan=\"3\">",
"        Diarrhea (often bloody), frequently accompanied by fever and abdominal cramps",
"       </td>",
"       <td>",
"        Isolation of organism of same serotype from clinical specimens from two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolation of organism from epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"5\">",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"       </td>",
"       <td rowspan=\"5\">",
"        30 min-8 hours, usually 2-4 hours",
"       </td>",
"       <td rowspan=\"5\">",
"        Vomiting, diarrhea",
"       </td>",
"       <td>",
"        Isolation of organism of same phage type from stool or vomitus of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Detection of enterotoxin in epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolation of &ge;10",
"        <sup>",
"         5",
"        </sup>",
"        organisms/g from epidemiologically implicated food, provided specimen properly handled",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Group A streptococcus",
"       </td>",
"       <td rowspan=\"3\">",
"        1-4 days",
"       </td>",
"       <td rowspan=\"3\">",
"        Fever, pharyngitis, scarlet fever, upper respiratory infection",
"       </td>",
"       <td>",
"        Isolation of organism of same M- or T-type from throats of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolation of organism of same M- or T-type from epidemiologically implicated food",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.cdc.gov/mmwr//mmwr.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for confirmation of food-borne disease outbreaks-IV",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiologic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Bacterial (cont.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        <em>",
"         Vibrio cholerae",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"5\">",
"        O1 or O139",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"5\">",
"        1-5 days",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"5\">",
"        Watery diarrhea, often accompanied by vomiting",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of toxigenic organism from stool or vomitus of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Significant rise in vibriocidal, bacterial-agglutinating, or antitoxin antibodies in acute- and early convalescent-phase sera among persons not recently immunized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Isolation of toxigenic organism from epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        non-O1 and non-O139",
"       </td>",
"       <td class=\"sublist_other\">",
"        1-5 days",
"       </td>",
"       <td class=\"sublist_other\">",
"        Watery diarrhea",
"       </td>",
"       <td class=\"sublist_other\">",
"        Isolation of organism of same serotype from stool of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Vibrio parahaemolyticus",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        4-30 hrs",
"       </td>",
"       <td rowspan=\"3\">",
"        Diarrhea",
"       </td>",
"       <td>",
"        Isolation of Kanagawa-positive organism from stool of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolation of &ge;10",
"        <sup>",
"         5",
"        </sup>",
"        Kanagawa-positive organisms/g from epidemiologically implicated food, provided specimen properly handled",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Yersinia enterocolitica",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        1-10 days, usually 4-6 days",
"       </td>",
"       <td rowspan=\"3\">",
"        Diarrhea, abdominal pain (often severe)",
"       </td>",
"       <td>",
"        Isolation of organism from clinical specimen of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isolation of pathogenic strain or organism from epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Chemical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        Marine toxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Ciguatoxin",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        1-48 hrs, usually 2-8 hrs",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Usually gastrointestinal symptoms followed by neurologic symptoms (including paresthesia of lips, tongue, throat, or extremities) and reversal of hot and cold sensation",
"       </td>",
"       <td class=\"sublist_other\">",
"        Demonstration of ciguatoxin in epidemiologically implicated fish",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Clinical syndrome among persons who have eaten a type of fish previously associated with ciguatera fish poisoning (eg, snapper, grouper, or barracuda)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.cdc.gov/mmwr//mmwr.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for confirmation of food-borne disease outbreaks-V",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiologic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Chemical (cont.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        Marine toxins (cont.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Scombroid toxin (histamine)",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        1 min-3 hrs, usually &lt;1 hr",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Flushing, dizziness, burning of mouth and throat, headache, gastrointestinal symptoms, urticaria, and generalized pruritus",
"       </td>",
"       <td class=\"sublist_other\">",
"        Demonstration of histamine in epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Clinical syndrome among persons who have eaten type of fish previously associated with histamine fish poisoning (eg, mahi-mahi or fish of order Scomboidei)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Paralytic or neurotoxic shellfish poison",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        30 min-3 hrs",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Paresthesia of lips, mouth or face, and extremities; intestinal symptoms or weakness, including respiratory difficulty",
"       </td>",
"       <td class=\"sublist_other\">",
"        Detection of toxin in epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Detection of large numbers of shellfish-poisoning-associated species of dinoflagellates in water from which epidemiologically implicated mollusks are gathered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Puffer fish, tetrodotoxin",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        10 min-3 hrs, usually 10-45 mins",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Paresthesia of lips, tongue, face, or extremities, often following numbness; loss of proprioception or \"floating\" sensations",
"       </td>",
"       <td class=\"sublist_other\">",
"        Demonstration of tetrodotoxin in epidemiologically implicated fish",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Clinical syndrome among persons who have eaten puffer fish",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Heavy metals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Antimony",
"       </td>",
"       <td rowspan=\"6\">",
"        5 min-8 hrs, usually &lt;1 hr",
"       </td>",
"       <td rowspan=\"6\">",
"        Vomiting, often metallic taste",
"       </td>",
"       <td rowspan=\"6\">",
"        Demonstration of high concentration of metal in epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cadmium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Copper",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Iron",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Tin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Zinc",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Monosodium glutamate (MSG)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3 mins-2 hrs, usually &lt;1 hr",
"       </td>",
"       <td>",
"        Burning sensation in chest, neck, abdomen, or extremities; sensation of lightness and pressure over face or heavy feeling in chest",
"       </td>",
"       <td>",
"        Clinical syndrome among persons who have eaten food containing MSG (ie, usually &ge;1.5 g MSG)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.cdc.gov/mmwr//mmwr.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for confirmation of food-borne disease outbreaks-VI",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiologic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Chemical (cont.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        Mushroom toxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Shorter-acting toxins:",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"6\">",
"        &le;2 hrs",
"       </td>",
"       <td class=\"sublist_other\">",
"        Usually vomiting and diarrhea, other symptoms differ with toxin:",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"6\">",
"        <p>",
"         Clinical syndrome among persons who have eaten mushroom identified as toxic type",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Demonstration of toxin in epidemiologically implicated mushroom or mushroom-containing food",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Muscimol",
"       </td>",
"       <td class=\"sublist_other\">",
"        Confusion, visual disturbance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Muscarine",
"       </td>",
"       <td class=\"sublist_other\">",
"        Salivation, diaphoresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Psilocybin",
"       </td>",
"       <td class=\"sublist_other\">",
"        Hallucinations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        <em>",
"         Coprinus artrementarius",
"        </em>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Disulfiram-like reaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Ibotenic acid",
"       </td>",
"       <td class=\"sublist_other\">",
"        Confusion, visual disturbance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Longer-acting toxin (eg,",
"        <em>",
"         Amanita",
"        </em>",
"        spp.)",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        6-24 hrs",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Diarrhea and abdominal cramps for 24 hrs followed by hepatic and renal failure",
"       </td>",
"       <td class=\"sublist_other\">",
"        Clinical syndrome among persons who have eaten mushroom identified as toxic type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Demonstration of toxin in epidemiologically implicated mushroom or mushroom-containing food",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Parasitic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Cryptosporidium parvum",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        2-28 days, median: 7 days",
"       </td>",
"       <td rowspan=\"3\">",
"        Diarrhea, nausea, vomiting, fever",
"       </td>",
"       <td>",
"        Demonstration of organism or antigen in stool or in small-bowel biopsy of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demonstration of organism in epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        <em>",
"         Cyclospora cayetanensis",
"        </em>",
"       </td>",
"       <td>",
"        1-11 days, median: 7 days",
"       </td>",
"       <td>",
"        Fatigue, protracted diarrhea, often relapsing",
"       </td>",
"       <td>",
"        Demonstration of organism in stool of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Giardia lamblia",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        3-25 days, median: 7 days",
"       </td>",
"       <td rowspan=\"3\">",
"        Diarrhea, gas, cramps, nausea, fatigue",
"       </td>",
"       <td>",
"        Two or more ill persons and detection of antigen in stool",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demonstration of organism in stool, duodenal contents, or small-bowel biopsy specimen",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Trichinella",
"        </em>",
"        spp.",
"       </td>",
"       <td rowspan=\"3\">",
"        1-2 days for intestinal phase; 2-4 wks for systemic phase",
"       </td>",
"       <td rowspan=\"3\">",
"        Fever, myalgia, periorbital edema, high eosinophil count",
"       </td>",
"       <td>",
"        Two or more ill persons and positive serologic test or demonstration of larvae in muscle biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demonstration of larvae in epidemiologically implicated meat",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.cdc.gov/mmwr//mmwr.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for confirmation of food-borne disease outbreaks-VII",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiologic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Viral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis A",
"       </td>",
"       <td>",
"        15-50 days, median: 28 days",
"       </td>",
"       <td>",
"        Jaundice, dark urine, fatigue, anorexia, nausea",
"       </td>",
"       <td>",
"        Detection of IgM anti-hepatitis A virus in serum from two or more persons who consumed epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Norwalk family of viruses, small round-structured viruses (SRSV)",
"       </td>",
"       <td rowspan=\"3\">",
"        15-77 hrs, usually 24-48 hrs",
"       </td>",
"       <td rowspan=\"3\">",
"        Vomiting, cramps, diarrhea, headache",
"       </td>",
"       <td>",
"        More than fourfold rise in antibody titer to Norwalk virus or Norwalk-like virus in acute and convalescent sera in most serum pairs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visualization of small, round-structured viruses that react with patient's convalescent sera but not acute sera - by immune electron microscopy. Assays based on molecular diagnostic (eg, polymerase chain reaction [PCR], probes, or assays for antigen and antibodies from expressed antigen) are available in reference laboratories.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        Astrovirus, calicivirus, others",
"       </td>",
"       <td>",
"        15-77 hrs, usually 24-48 hrs",
"       </td>",
"       <td>",
"        Vomiting, cramps, diarrhea, headache",
"       </td>",
"       <td>",
"        Visualization of small, round-structured viruses that react with patient's convalescent sera but not acute sera - by immune electron microscopy. Assays based on molecular diagnostics (eg, PCR, probes, or assays for antigen and antibodies from expressed antigen) are available in reference laboratories.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.cdc.gov/mmwr//mmwr.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_23_32114=[""].join("\n");
var outline_f31_23_32114=null;
var title_f31_23_32115="Mitral valve prolapse four chamber echocardiogram";
var content_f31_23_32115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/65137/4chmvpro_conv.mp4?title=Mitral+valve+prolapse+four+chamber+echocardiogram\" style=\"width:328px;height:248px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral valve prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 253px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four chamber view from a 2-D echocardiogram shows prolapse of the posterior mitral valve leaflet. The left atrium and ventricle are dilated, suggesting that significant mitral regurgitation is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_23_32115=[""].join("\n");
var outline_f31_23_32115=null;
var title_f31_23_32116="Glatiramer acetate: Patient drug information";
var content_f31_23_32116=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Glatiramer acetate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"     see \"Glatiramer acetate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Copaxone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F176077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Copaxone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691352",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the number of setbacks with MS (multiple sclerosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to glatiramer acetate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698092",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. May happen within a minute of the shot and lasts about 15 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sweating a lot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hives.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694933",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Give at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store brown vials in a refrigerator or at room temperature. If stored at room temperature, throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store vials of sterile water at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12509 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_23_32116=[""].join("\n");
var outline_f31_23_32116=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176076\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176077\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029427\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029429\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029428\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029433\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029434\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029436\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029431\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029432\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029437\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029438\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=related_link\">",
"      Glatiramer acetate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_23_32117="Iobenguane: Drug information";
var content_f31_23_32117=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Iobenguane: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/44/29379?source=see_link\">",
"    see \"Iobenguane: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6860203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AdreView&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6815128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6815282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Thyroid protective agents (SSKI, Lugol's solution or potassium iodide), should be given at least 1 hour prior to administration. Perform whole body planar scintigraphy imaging 18-30 hours after Iobenguane I 123 administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Radioimaging:",
"     </b>",
"     I.V.: 10 mCi (370 MBq)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6815323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Thyroid protective agents (SSKI, Lugol's solution or potassium iodide), should be given at least 1 hour prior to administration. Perform whole body planar scintigraphy imaging 18-30 hours after Iobenguane I 123 administration.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Radioimaging:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1 month to 16 years and &lt;70 kg: Dose according to body weight; see table.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &lt;16 years and &ge;70 kg: 10 mCi (370 MBq)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;16 years: Refer to adult dosing",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Iobenguane I 123 Pediatric Dosing by Body Weight: (Children 1 Month to 16 Years and &lt;70 kg)",
"     </caption>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"140\">",
"     </col>",
"     <col align=\"center\" width=\"140\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Weight (kg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         mCi Dose",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         MBq Dose",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         37",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1.4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         52",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1.9",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         70",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         85.1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         99.9",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         118.4",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         14",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         133.2",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         16",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         148",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         18",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         162.8",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         170.2",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         22",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         185",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         24",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         196.1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         26",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         207.2",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         28",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5.8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         214.6",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6.2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         229.4",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         32",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         240.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         34",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6.8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         251.6",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         36",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         262.7",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         38",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         270.1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         281.2",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         42",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         288.6",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         44",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         296",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         46",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8.2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         303.4",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         48",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         314.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8.8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         325.6",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         52-54",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         333",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         56-58",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9.2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         340.4",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60-62",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         355.2",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         64-66",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9.8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         362.6",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         68",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9.9",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         366.3",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6815343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15962253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). However, radiation exposure may be increased in patients with severe renal impairment, use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15962254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6815353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AdreView&trade;: Iobenguane sulfate 0.08 mg and I 123 74 MBq (2 mCi) per mL (5 mL) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6815126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6815349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer intravenously over 1-2 minutes. May flush with NS to ensure full delivery of dose. Prior to administration, a thyroid-protective agent should be started. Ensure adequate hydration before and after treatment.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6815131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As an adjunct to other diagnostic tests, in the detection of primary or metastatic pheochromocytoma or neuroblastoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15245845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6815142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &lt;1% (Limited to important or life-threatening): Dizziness, flushing, hypersensitivity (rare), injection site hemorrhage, pruritus, rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6815137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iobenguane or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6815138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Have been reported. Use extreme caution in patients with iodine or iodine-contrast agent hypersensitivity. Appropriate equipment and emergency medications should be available during use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypertension: Use with caution in patients with hypertension; may increase blood pressure and heart rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; safety and efficacy have not been established. Patients with severe renal impairment may have delayed elimination, therefore, decreasing quality of images. Not dialyzable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Norepinephrine uptake inhibitors: If possible, discontinue medications that inhibit norepinephrine uptake prior to iobenguane I 123 administration; allow at least 5 half-lives to elapse. These medications may interfere with the uptake of iobenguane I 123 in neuroendocrine tumors leading to false-negative results.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in infants &lt;1 month of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Benzyl alcohol: Contains benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Administer thyroid blocking medications (eg, potassium iodide oral solution, potassium perchlorate) at least 1 hour prior to administration; long-term risk for thyroid neoplasia can occur from failure to block thyroid uptake of iodine 123. Patients should be adequately hydrated prior to dosing; instruct patients to void frequently for 48 hours following administration to decrease radiation exposure.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6833886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May diminish the therapeutic effect of Iobenguane I 123.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Selective Norepinephrine Reuptake Inhibitor): May diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cocaine: May diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: May diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6815132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6815133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Radiopharmaceuticals have the potential to cause fetal harm. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6815135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6815136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iodine 123 is excreted into human milk, therefore, due to potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended. May consider interrupting breast-feeding for 6 days after administration of iobenguane I 123 to minimize risk to infant.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6815348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some dietary sources of iodine include cow's milk and dairy products, fish, seaweed, eggs, chocolate, and iodized salt.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (AdreView Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mci/5 mL (5 mL): $4723.22",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6815352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pulse and blood pressure prior to administration and intermittently for 30 minutes following; monitor for hypersensitivity reaction",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6815147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iobenguane is structurally similar to norepinephrine and therefore is taken up and stored in adrenergic tissue such as adrenal medulla, heart, liver, lungs, salivary glands, and spleen. Iobenguane is bound to radioactive iodine in order to obtain organ and tissue images.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6815149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Increased in adrenergically innervated tissues (eg, heart, salivary glands, adrenal medulla)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Has not been characterized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Iodine 123: 13.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (70 % to 90%) within 4 days (normal renal function); feces &lt;1%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9084 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-5480875BC6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_23_32117=[""].join("\n");
var outline_f31_23_32117=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6860203\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815128\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815282\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815323\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815343\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962253\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962254\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815353\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815126\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815349\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815131\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245845\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815142\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815137\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815138\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299525\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6833886\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815132\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815133\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815135\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815136\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815348\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321886\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815352\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815147\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6815149\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9084\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9084|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/44/29379?source=related_link\">",
"      Iobenguane: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_23_32118="Clopidogrel generalized exanthema";
var content_f31_23_32118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F83637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F83637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clopidogrel hypersensitivity - generalized rash",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Cheema AN, Mohammad A, Hong T, et al. Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation. J Am Coll Cardiol 2011; 58:1445. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_23_32118=[""].join("\n");
var outline_f31_23_32118=null;
var title_f31_23_32119="p50 subunit of NF kB CD14 cells";
var content_f31_23_32119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F73035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F73035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    p50 subunit of nuclear factor-kappa B (NF-kB) in CD14 cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sublining tissue from a patient with rheumatoid arthritis studied by double immunohistochemistry. Brown-stained nuclei contain the p50 subunit of nuclear factor-kappa B (NF-kB); blue staining designates CD14-positive cells. Most CD14-positive cells contain the p50 subunit of NF-kB.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ellen M Gravallese, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_23_32119=[""].join("\n");
var outline_f31_23_32119=null;
var title_f31_23_32120="Urodynamic evaluation of women with incontinence";
var content_f31_23_32120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Urodynamic evaluation of women with incontinence",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/23/32120/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/23/32120/contributors\">",
"     George Flesh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/23/32120/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/23/32120/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/23/32120/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/23/32120/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/23/32120/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urodynamics refers to a group of tests used to assess function of the urinary tract by measuring various aspects of urine storage and evacuation (",
"    <a class=\"graphic graphic_table graphicRef75195 \" href=\"mobipreview.htm?15/6/15467\">",
"     table 1",
"    </a>",
"    ). Some specific types of urodynamic testing are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cystometry (or cystometrogram) evaluates bladder function by measuring pressure and volume of fluid in the bladder during filling, storage, and voiding.",
"     </li>",
"     <li>",
"      Uroflowmetry measures the rate of urine flow.",
"     </li>",
"     <li>",
"      Urethral pressure profile tests urethral function.",
"     </li>",
"     <li>",
"      Leak point pressure determines the bladder or abdominal pressure when leakage occurs due to increased abdominal pressure (Valsalva or cough) to assess urethral resistance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The purpose of urodynamic testing is to aid in understanding physiologic mechanisms of lower urinary tract dysfunction, thereby improving the accuracy of diagnosis and facilitating targeted treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical evaluation with urodynamics may lead to a more accurate diagnosis of incontinence type [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. A meta-analysis including several thousand women reported the symptom of stress incontinence, when compared against a urodynamic diagnosis, was 91 percent sensitive, but only 51 percent specific in diagnosing pure stress incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/6\">",
"     6",
"    </a>",
"    ]. For urge incontinence, history alone was 73 percent sensitive, but only 55 percent specific.",
"   </p>",
"   <p>",
"    In a chart review study of women with urinary incontinence, the probability of a change in treatment plan with, versus without, urodynamic data was 27 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a Cochrane review concluded there were insufficient data from randomized studies to determine whether treatment of urinary incontinence according to a urodynamic-based diagnosis was more effective than treatment based upon history and examination alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous pitfalls in urodynamic testing limit its value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/9\">",
"     9",
"    </a>",
"    ]. Some fundamental problems include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of standardization of technical details, such as patient position, type of pressure sensor, and filling rate. These variables significantly affect results.",
"     </li>",
"     <li>",
"      The artificial situation of the urodynamic laboratory, which produces nonphysiologic results in some patients.",
"     </li>",
"     <li>",
"      Use of a transurethral catheter can unmask stress incontinence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inconsistent reproducibility of test results in the same patient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The wide range of physiologic values in normal, asymptomatic patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The absence of a specific abnormality during urodynamic testing does not exclude its existence, and not all abnormalities found during urodynamics are clinically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, a urodynamic test cannot be considered definitive without placing it in the context of other findings. A complete patient evaluation should consist of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History",
"     </li>",
"     <li>",
"      Physical examination",
"     </li>",
"     <li>",
"      Urine culture",
"     </li>",
"     <li>",
"      Microscopic urinalysis",
"     </li>",
"     <li>",
"      Measurement of postvoid residual urine volume",
"     </li>",
"     <li>",
"      Urinary diary (a record of volume and frequency of fluid intake and voiding over one to seven days)",
"     </li>",
"     <li>",
"      Cotton swab test",
"     </li>",
"     <li>",
"      Perineal pad test (to quantify leakage over a 1- to 24-hour period by measuring changes in pad weight). The range of maximum weight change reported in continent women is 1 to 8 g over 24 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for urodynamic testing remain controversial. Current consensus statements and practice recommendations do not recommend initial urodynamic tests prior to conservative treatment of stress incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/14\">",
"     14",
"    </a>",
"    ]. However, some situations in which such testing may be useful include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis, especially with respect to type of urinary incontinence, remains unclear after the initial history and physical examination.",
"     </li>",
"     <li>",
"      The patient's symptoms do not correlate with objective physical findings.",
"     </li>",
"     <li>",
"      The patient fails to improve with treatment.",
"     </li>",
"     <li>",
"      Clinical trials where objective confirmation of diagnosis is important.",
"     </li>",
"     <li>",
"      Surgical intervention is planned.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The last indication is the most controversial. On one hand, an uncertain diagnosis may be acceptable if the recommended therapy has little or no risk (eg, pelvic floor exercise, biofeedback, bladder training, pessary, or anticholinergic drugs), but urodynamic confirmation of the diagnosis is desirable before a surgical treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists (ACOG) concluded that urodynamic testing is often recommended to confirm the diagnosis when surgery for stress urinary incontinence is planned, unless the history and physical examination are uncomplicated and consistent with the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/15\">",
"     15",
"    </a>",
"    ]. By comparison, others have concluded that urodynamic testing before surgery in women with signs and symptoms of stress urinary incontinence symptoms and pelvic organ prolapse does not improve cure rates and is not cost-effective compared to basic office evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/16\">",
"     16",
"    </a>",
"    ]. As an example, one study found that a simple standing cough test was just as reliable as multichannel cystometry in detecting genuine stress incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteriuria has been reported in 3 to 8 percent of women after urodynamic testing, but is usually transient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Prophylactic antibiotics are not necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CYSTOMETRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystometry measures bladder pressure during bladder filling. It is used to assess detrusor activity and bladder sensation, capacity, and compliance. Cystometry can be done with one channel measuring bladder pressure alone or with an additional channel that simultaneously measures abdominal pressure through the rectum or vagina. The advantage of the multichannel test is that it can discriminate between changes in abdominal versus bladder pressure by electronically subtracting the abdominal component from intravesical pressure.",
"   </p>",
"   <p>",
"    Only a multichannel test can show that a rise in bladder pressure is due to detrusor contraction rather than tensing of the abdominal wall. This information is important for avoiding a false impression of detrusor overactivity. As an example, detrusor overactivity during single channel cystometry is not reproducible by multichannel testing in 40 percent of women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/22\">",
"     22",
"    </a>",
"    ]. Thus, most, but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/23\">",
"     23",
"    </a>",
"    ], experts believe that the multichannel test result is the most reliable for evaluating women with incontinence.",
"   </p>",
"   <p>",
"    Some urodynamic machines can also record urethral pressure with a second sensor on the bladder catheter (see below). This allows electronic calculation of urethral closure pressure, which is the difference between urethral and bladder pressures. Leakage usually occurs when bladder pressure exceeds urethral pressure. However, the clinical value of this measurement has not been proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common reason to do cystometry is to distinguish detrusor overactivity (involuntary contractions of the bladder) from stress incontinence (leakage due to an increase in abdominal pressure) (",
"    <a class=\"graphic graphic_figure graphicRef65452 \" href=\"mobipreview.htm?4/29/4562\">",
"     figure 1",
"    </a>",
"    ). The test can also identify patients with abnormalities of bladder sensation and mixed incontinence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Data",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Continence Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/24\">",
"     24",
"    </a>",
"    ] defines cystometry data points as the volume at which the patient notes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First desire to void (the patient is aware of bladder filling and feels she could void)",
"     </li>",
"     <li>",
"      Normal desire to void (the patient wants to void at the next convenient moment, but could delay if necessary)",
"     </li>",
"     <li>",
"      Urgency (a strong desire to void accompanied by fear of leakage or pain)",
"     </li>",
"     <li>",
"      Maximum cystometric capacity (the patient feels she can no longer delay micturition)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other information includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compliance (the change in volume divided by change in detrusor pressure)",
"     </li>",
"     <li>",
"      Overactive bladder (any contractions, spontaneous or provoked, are abnormal during filling)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Normal observations and results",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal bladder should not begin contractions during filling and should initially expand without resistance. The urethral sphincter should relax and open when the patient wants to initiate voiding, accompanied by detrusor contractions. During voiding, detrusor contraction should be smooth and lead to a steady urine stream.",
"   </p>",
"   <p>",
"    There are no recognized standards for normal values. However, a reasonable range for first desire to void is 100 to 200 cc, normal desire to void 150 to 350 cc, urgency 250 to 500 cc, and maximum cystometric capacity 300 to 600 cc. A small rise in detrusor pressure (ie, less than 10 to 15 cm of water) without undue sensation of urgency up to a capacity of 400 to 500 is also normal. Values outside these ranges do not necessarily indicate pathology, but could confirm a problem in symptomatic patients. Test results must correlate with symptoms to be meaningful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Common abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the more common bladder abnormalities and their cytometric findings are described below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Detrusor overactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detrusor overactivity (overactive bladder) can be diagnosed if there is urgency or leakage with a detrusor contraction that the patient cannot suppress. The involuntary detrusor contractions during the filling phase may be spontaneous or provoked by maneuvers such as posture change from prone to standing, toe raises, running water, or hand washing. In women with neurologic disease, uninhibited detrusor contractions are termed neurogenic detrusor overactivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Genuine stress incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genuine stress incontinence is characterized by leakage that occurs with an increase in abdominal pressure, such as coughing or Valsalva, without a rise in true detrusor pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Idiopathic sensory urgency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic sensory urgency should be considered in women with sensory parameters below the normal range. Symptoms include urgency at a low bladder volume, low bladder capacity, and frequency. However, patients with stress and urge incontinence also often have low sensory volumes because they adapt to the risk of leakage by emptying the bladder frequently. These latter disorders can be excluded by absence of the findings described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Neurologic abnormality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic abnormality is suggested by an above normal capacity and high volume at first desire. A hypotonic bladder fails to empty adequately due to inadequate detrusor pressure. Flow rate is usually low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Interstitial cystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial cystitis is characterized by low volume at normal desire, low volume urgency, and low capacity. Some patients also have poor compliance. Normal compliance allows bladder filling to occur up to maximum capacity with minimal (5 to 10 cm H2O) change in intravesical pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Elevated baseline pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective study of patients who had minimally invasive slings for stress incontinence reported that 56 percent of women with a detrusor pressure &gt;15 cm during the filling phase of cystometry developed de novo urge incontinence after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal technique for performing cystometry has not been determined; thus, methods vary among centers. There is no preprocedure preparation. In general, having the patient in a sitting or standing position is more desirable than lying prone because these positions simulate stresses on the bladder that typically occur in daily life. Standing or sitting positions increased the detection of detrusor overactivity in most studies by 33 to 100 percent, according to a systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient begins by emptying her bladder as much as possible, then a thin plastic catheter is slowly inserted into the urethra until it reaches the bladder. Measurements are taken of the residual urine volume and bladder pressure.",
"   </p>",
"   <p>",
"    Water or normal saline at room temperature is typically used to fill the bladder, although warm or cold fluid may be useful to provoke detrusor overactivity. Use of carbon dioxide has fallen into disfavor because it is less physiologic, compressible, dissolves in urine to form carbonic acid, and does not permit stress testing or a voiding study.",
"   </p>",
"   <p>",
"    Most clinicians fill the bladder through the catheter at a rate of 50 to 100 cc per minute. Faster filling rates (greater than 100",
"    <span class=\"nowrap\">",
"     cc/min)",
"    </span>",
"    are more likely to provoke detrusor overactivity. The woman is asked to describe sensations during filling, including when the first feeling of bladder fullness occurs.",
"   </p>",
"   <p>",
"    A variety of transducers is available. Water-filled balloon catheters or water perfusion catheters are inexpensive and disposable. Microtransducer catheters are more accurate, but are more expensive, require sterilization, and can produce artifacts depending upon the orientation of the transducer to the bladder or urethral mucosa. A comparison of air-charged and microtransducer catheters in the evaluation of urethral function showed high concordance for maximum urethral closure pressure and valsalva leak point pressure, but not for functional urethral length [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Provocative maneuvers, such as coughing, Valsalva, heel bouncing, jumping, walking in place, change in posture, hand washing, and listening to running water are helpful for determining if they cause leakage and whether the leakage is related to uninhibited detrusor contractions or stress incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the bladder is completely full, the woman is asked to begin voiding, and measurements are made of pressure, volume, and flow rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Postprocedure care",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the procedure, the patient may note urinary frequency, urgency, hematuria, or dysuria for a day. Increasing fluid intake helps to flush out the bladder, but caffeinated, carbonated, or alcoholic beverages should be avoided because they may irritate the bladder lining. Signs of infection, such as fever, chills, low back pain, or persistent blood in the urine, should be reported to the clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Modifications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Videourodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;This technique is similar to conventional cystometry, but with the addition of a radio-opaque filling medium, video recorder, and x-ray equipment. Videourodynamics may offer information beyond conventional urodynamics in complicated neurologic conditions, but most authorities believe it is seldom indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/30\">",
"     30",
"    </a>",
"    ]. The disadvantages are radiation exposure, cost, and the extra technical support required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Ambulatory urodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulatory testing can be performed by using commercially available systems in which an ambulatory patient wears an indwelling catheter connected to a microcomputer. The advantage over conventional cystometry is that the home environment reflects the patient's functional status more realistically than the laboratory. Several studies have shown that ambulatory urodynamics are more sensitive than conventional urodynamics in diagnosing detrusor overactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. One study showed that ambulatory monitoring was an effective second-line investigation for diagnosing incontinence in difficult cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there are several disadvantages to this method. It is costly and artifacts can be produced by catheter movement, leading to difficulty interpreting data and inaccurate diagnoses. As an example, one study found that 69 percent of healthy, asymptomatic women were diagnosed with detrusor overactivity on ambulatory monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/35\">",
"     35",
"    </a>",
"    ]. At this time, ambulatory urodynamics is useful in research, but not in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     UROFLOWMETRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uroflowmetry measures urine volume voided over time. It can be done with or without a pressure-flow study (see below), which measures detrusor pressure during voiding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal voiding is much more common in men than in women. Nevertheless, uroflowmetry is usually done as part of a complete urodynamic evaluation in women. It can be useful in clinical situations, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequency, urgency, and urge incontinence as some of these patients have outlet obstruction.",
"     </li>",
"     <li>",
"      Voiding difficulty, hesitancy, or difficulty maintaining the urine stream, which can also be due to outlet obstruction (from previous pelvic surgery or urethral kinking with anterior vaginal wall prolapse) or weak detrusor (as in neurologic diseases).",
"     </li>",
"     <li>",
"      Planned pelvic surgery because poor uroflow may be a predictor of postoperative voiding difficulty after incontinence surgery or radical pelvic surgery. This information allows for preoperative counseling or training in self-catheterization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/38\">",
"       38",
"      </a>",
"      ]; however, the predictive value of uroflowmetry is controversial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the physician and nurse have left the room, the patient voids into a special commode that measures the amount and rate of urine flow. Although there are no universally accepted standards, a normal uroflow test consists of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Volume greater than 200 mL over 15 to 30 seconds",
"     </li>",
"     <li>",
"      Maximum flow rate greater than 15",
"      <span class=\"nowrap\">",
"       mL/sec",
"      </span>",
"     </li>",
"     <li>",
"      Continuous single curve (as opposed to short spikes) of flow",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Flow rates less than 15",
"    <span class=\"nowrap\">",
"     mL/sec",
"    </span>",
"    may indicate outlet obstruction, detrusor weakness, or significant Valsalva effort during voiding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients are unable to void normally in the artificial conditions of the urodynamics laboratory; thus, it is important to ask the patient if she feels that her void was typical for her, especially if an abnormal pattern is observed. If the patient feels the test was atypical, it should be repeated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PRESSURE-FLOW STUDY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pressure-flow study measures both bladder pressure and urinary flow. The purpose of a pressure-flow study is to determine the mechanism of abnormal voiding revealed by a low flow rate on uroflowmetry. If the detrusor pressure is high (&gt;50 cm H2O), urethral overactivity (detrusor-sphincter dyssynergia) or urethral obstruction (stricture or tumor) may be present. The most common cause of obstructed voiding in females is prolapse of the anterior vaginal wall, which can cause kinking of the urethra when the bladder descends more than the urethra. In addition, previous pelvic surgery can cause bladder denervation and a weak detrusor muscle. The most common use of the pressure-flow study in women is to determine the cause of voiding dysfunction after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/41\">",
"     41",
"    </a>",
"    ]. It may be performed in men with clinical manifestations of prostate disease in whom there is reason to suspect some problem other than, or in addition to, benign prostatic hyperplasia.",
"   </p>",
"   <p>",
"    One study that compared women with bladder outlet obstruction to normal controls reported a maximum detrusor pressure &gt;25 cm H2O gave the greatest sensitivity and specificity, &gt;60 percent for detection of obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/42\">",
"     42",
"    </a>",
"    ]. A uroflow &lt;12",
"    <span class=\"nowrap\">",
"     mL/sec",
"    </span>",
"    gave equal sensitivity, specificity and accuracy (68 percent) for predicting obstruction.",
"   </p>",
"   <p>",
"    A pressure-flow study can be done as an extension of cystometry when catheters are already in place to measure detrusor and abdominal pressure. The patient voids around the urethral catheter into a commode, which simultaneously measures uroflow.",
"   </p>",
"   <p>",
"    If the patient has an acontractile or poorly contractile detrusor, she will have a low flow rate (&lt;15",
"    <span class=\"nowrap\">",
"     cc/sec",
"    </span>",
"    maximum flow) and little or no rise in true detrusor pressure. Voiding occurs mainly by abdominal straining. Since many patients use Valsalva to aid voiding, a rise in abdominal pressure alone does not indicate a problem. Detrusor acontractility is often due to a neurologic abnormality, such as spinal cord injury or multiple sclerosis, but it may be idiopathic.",
"   </p>",
"   <p>",
"    Test results are difficult to assess because of the difficulty of voiding around the catheter, as well as the artificial surroundings of the urodynamics laboratory. There are no accepted standards for the method and interpretation of pressure-flow studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     URETHRAL PRESSURE PROFILE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pressure in the urethra should be equal to or greater than the bladder pressure during bladder filling. When the bladder and urethra are in their proper anatomic location, increases in intraabdominal pressure will also increase urethral pressure, thereby preventing leakage. Low urethral pressure can be associated with incontinence and is related to aging, hypoestrogenic state, multiparity, and previous significant urogynecological operations.",
"   </p>",
"   <p>",
"    The urethral pressure profile (UPP) measures the intraluminal pressure along the entire length of the urethra with the bladder at rest. A special catheter with an intravesical and an intraurethral pressure transducer and side openings near its tip is perfused and slowly withdrawn from the bladder (",
"    <a class=\"graphic graphic_figure graphicRef65452 \" href=\"mobipreview.htm?4/29/4562\">",
"     figure 1",
"    </a>",
"    ). The transducers are usually brought out to the external urethral meatus at a rate of 1",
"    <span class=\"nowrap\">",
"     mm/sec",
"    </span>",
"    by a mechanical pulling device. The pressure necessary to maintain a constant flow provides an assessment of the activity of the urethral wall.",
"   </p>",
"   <p>",
"    The clinical purpose of the urethral pressure profile (UPP) is to help distinguish intrinsic sphincter deficiency from genuine stress incontinence by measuring:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maximum urethral pressure (the highest pressure measured)",
"     </li>",
"     <li>",
"      Maximum urethral closure pressure (the difference between maximum urethral pressure and intravesical pressure)",
"     </li>",
"     <li>",
"      Functional urethral length (the length where the urethral pressure exceeds the intravesical pressure)",
"     </li>",
"     <li>",
"      Pressure-transmission ratio (the increment in urethral pressure on stress as a percentage of the simultaneous increment in vesical pressure) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The UPP has limited clinical value because of a lack of standardized technique and equipment, as well as variable interpretation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/15\">",
"     15",
"    </a>",
"    ]. Upright posture and increased bladder volume both increase urethral pressure. The size and stiffness of the catheter and the type of pressure transducer also affect the UPP. When microtransducers are used, pressures vary depending upon the orientation of the transducer, with anterior orientation producing higher pressures and posterior orientation, lower. Therefore, the study is usually done with the transducer in the lateral position.",
"   </p>",
"   <p>",
"    In addition, detrusor overactivity can affect urethral function resulting in decreases in functional urethral length and pressure transmission ratio with bladder filling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/43\">",
"     43",
"    </a>",
"    ]. Thus, detrusor overactivity needs to be treated to obtain a valid UPP.",
"   </p>",
"   <p>",
"    Since the UPP is measuring the urethra at rest, it is of limited value in arriving at a diagnosis in the dynamic situation of incontinence. No single parameter of the UPP is useful in diagnosing stress incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/12\">",
"     12",
"    </a>",
"    ]. The pressure-transmission ratio also cannot discriminate between stress incontinence patients and controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A few studies have indicated that a low maximum urethral closure pressure (usually &lt;20 or &lt;30 cm H2O) is a predictor of poor outcome for retropubic suspension surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/45-47\">",
"     45-47",
"    </a>",
"    ], and, therefore, some advocate a sling procedure for patients with low urethral closure pressure and urethral hypermobility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. This reasoning would make the UPP clinically significant. However, there is a strong trend toward sling procedures for all cases of stress incontinence, with or without low urethral pressure, which makes the UPP increasingly irrelevant to choice of surgical procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/50\">",
"     50",
"    </a>",
"    ]. Some experts recommend placing a sling slightly closer to the urethra in patients with low urethral closure pressure or low abdominal leak point pressure, but there are no data to support this recommendation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/10/43177?source=see_link\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intrinsic sphincter deficiency without urethral hypermobility is usually treated with periurethral bulking injections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44409?source=see_link\">",
"     \"Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment\"",
"    </a>",
"    .) A UPP with low maximum pressure could provide supportive evidence to justify this method of treatment.",
"   </p>",
"   <p>",
"    Women younger than 25 have a mean maximum urethral closure pressure of 90 cm H2O, while women older than 64 have a mean of 65 cm H2O [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/51\">",
"     51",
"    </a>",
"    ]. The average functional urethral length declines after menopause. Estrogen increases urethral length and maximum urethral pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/52\">",
"     52",
"    </a>",
"    ]. However, there is no evidence that estrogen decreases incontinence in women with intrinsic sphincter deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     LEAK POINT PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leak point pressure refers to the amount of abdominal pressure required to overcome urethral resistance and produce urine leakage when the patient is not trying to void. The pressure can be produced by Valsalva or cough. Unlike the urethral pressure profile, the leak point pressure reflects urethral function in the dynamic situation that produces incontinence.",
"   </p>",
"   <p>",
"    Leak point pressure is used to assess intrinsic sphincter function. It is more reliable than the urethral pressure profile for diagnosis of intrinsic sphincter deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Confirmation of this diagnosis can be important in selecting the correct surgical approach. Intrinsic sphincter deficiency is treated with a sling procedure or periurethral injections, rather than retropubic suspension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/10/43177?source=see_link\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal method for performing leak point pressure is controversial. There is no standard. Variables include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bladder volume (increasing volume decreases leak point) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patient position (upright leak point is lower than supine)",
"     </li>",
"     <li>",
"      Catheter size (a 3 French catheter produces a lower leak point than an 8 French) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/55\">",
"       55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Location of the catheter (intravesical versus vaginal or abdominal. Transurethral catheters are obstructive and increase leak point pressure) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Method of determining leak point (visual, fluoroscopic or electronic)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A commonly used technique employs eight French microtip transducers at a bladder volume of 200 cc, in the sitting position, with leak point determined by visual observation. Both Valsalva and cough pressure profile (a series of increasingly strong coughs) are used to determine leak point. In the same patient, cough leak point is often different from Valsalva leak point. Furthermore, some patients involuntarily contract the levator muscles during valsalva or cough, which can increase leak point pressure. Despite these difficulties, many clinicians use a leak point pressure below 60 cm H2O to confirm the diagnosis of intrinsic sphincter deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32120/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     POSTVOID RESIDUAL VOLUME",
"    </span>",
"    &nbsp;&mdash;&nbsp;This measurement is made either by straight catheterization or by bladder ultrasound. Small portable ultrasounds specifically for postvoid residual measurement are available. A normal patient should have the ability to void at least 80 percent of the total bladder volume and have residual urine less than 50 cc immediately after voiding. A high residual urine on repeated determinations indicates outlet obstruction or poor detrusor contractility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     ELECTROPHYSIOLOGIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various electrophysiologic tests have also been used to evaluate lower urinary tract dysfunction. They have been employed mainly in the context of research, rather than clinical care.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electromyography (EMG) is the study of electrical potentials generated by depolarization of muscle. This can be done with surface electrodes, a needle inserted into urethral sphincter, a monopolar electrode inside the urethra, a concentric needle inserted into the urethral sphincter, or a single fiber to record action potentials from individual muscle fibers.",
"     </li>",
"     <li>",
"      Nerve conduction studies (NCS) examine nerve conduction rates from a stimulus to a receptor at a distal site. Pudendal nerve terminal motor latency and perineal nerve terminal motor latency (the time elapsed between initiating an impulse and its arrival at nerve's end) can be determined.",
"     </li>",
"     <li>",
"      Evoked potentials are the sum of potentials recorded in central nervous tissue (spinal cord or cortex) after stimulation of a peripheral site such as the perineum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In clinical practice, these tests are rarely helpful except in some neurologic disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urodynamic testing is only one part of an evaluation that includes history, physical examination, urine culture, and post-void residual.",
"     </li>",
"     <li>",
"      Urodynamic testing is helpful when the diagnosis of lower urinary tract dysfunction is unclear, when objective findings do not correlate with subjective symptoms, when a patient fails to improve with treatment, and when surgical treatment is planned.",
"     </li>",
"     <li>",
"      The main components of urodynamic testing are cystometry (measuring bladder pressure during filling of the bladder), uroflowmetry (measuring urine flow over time), pressure-flow study (determining whether poor flow is due to obstruction or detrusor weakness), and urethral pressure profile or leak point pressure (for diagnosis of intrinsic sphincter deficiency).",
"     </li>",
"     <li>",
"      All urodynamic tests have uncontrolled variables, lack of standardization, and artifacts. Therefore, they must be interpreted with caution in the context of a patient's entire clinical picture.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/1\">",
"      Ouslander J, Staskin D, Raz S, et al. Clinical versus urodynamic diagnosis in an incontinent geriatric female population. J Urol 1987; 137:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/2\">",
"      Byrne DJ, Stewart PA, Gray BK. The role of urodynamics in female urinary stress incontinence. Br J Urol 1987; 59:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/3\">",
"      Cantor TJ, Bates CP. A comparative study of symptoms and objective urodynamic findings in 214 incontinent women. Br J Obstet Gynaecol 1980; 87:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/4\">",
"      Summitt RL Jr, Stovall TG, Bent AE, Ostergard DR. Urinary incontinence: correlation of history and brief office evaluation with multichannel urodynamic testing. Am J Obstet Gynecol 1992; 166:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/5\">",
"      Weidner AC, Myers ER, Visco AG, et al. Which women with stress incontinence require urodynamic evaluation? Am J Obstet Gynecol 2001; 184:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/6\">",
"      Jensen JK, Nielsen FR Jr, Ostergard DR. The role of patient history in the diagnosis of urinary incontinence. Obstet Gynecol 1994; 83:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/7\">",
"      Ward RM, Hampton BS, Blume JD, et al. The impact of multichannel urodynamics upon treatment recommendations for female urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/8\">",
"      Glazener CM, Lapitan MC. Urodynamic investigations for management of urinary incontinence in adults. Cochrane Database Syst Rev 2002; :CD003195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/9\">",
"      Vereecken RL. A critical view on the value of urodynamics in non-neurogenic incontinence in women. Int Urogynecol J Pelvic Floor Dysfunct 2000; 11:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/10\">",
"      Maniam P, Goldman HB. Removal of transurethral catheter during urodynamics may unmask stress urinary incontinence. J Urol 2002; 167:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/11\">",
"      Lose, G, Thyssen, H. Reproducibility of cystometry and pressure-flow parameters in female patients. Neurourol Urodyn 1996; 15:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/12\">",
"      Versi E. Discriminant analysis of urethral pressure profilometry data for the diagnosis of genuine stress incontinence. Br J Obstet Gynaecol 1990; 97:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/13\">",
"      Karantanis E, O'Sullivan R, Moore KH. The 24-hour pad test in continent women and men: normal values and cyclical alterations. BJOG 2003; 110:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/14\">",
"      Rosier PF, Gajewski JB, Sand PK, et al. Executive summary: The International Consultation on Incontinence 2008--Committee on: \"Dynamic Testing\"; for urinary incontinence and for fecal incontinence. Part 1: Innovations in urodynamic techniques and urodynamic testing for signs and symptoms of urinary incontinence in female patients. Neurourol Urodyn 2010; 29:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/15\">",
"      American College of Obstetricians and Gynecologists. Urinary incontinence in women. Obstet Gynecol 2005; 105:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/16\">",
"      Weber AM, Walters MD. Cost-effectiveness of urodynamic testing before surgery for women with pelvic organ prolapse and stress urinary incontinence. Am J Obstet Gynecol 2000; 183:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/17\">",
"      Wall LL, Wiskind AK, Taylor PA. Simple bladder filling with a cough stress test compared with subtracted cystometry for the diagnosis of urinary incontinence. Am J Obstet Gynecol 1994; 171:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/18\">",
"      Bombieri L, Dance DA, Rienhardt GW, et al. Urinary tract infection after urodynamic studies in women: incidence and natural history. BJU Int 1999; 83:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/19\">",
"      Brostrom S, Jennum P, Lose G. Morbidity of urodynamic investigation in healthy women. Int Urogynecol J Pelvic Floor Dysfunct 2002; 13:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/20\">",
"      Baker KR, Drutz HP, Barnes MD. Effectiveness of antibiotic prophylaxis in preventing bacteriuria after multichannel urodynamic investigations: a blind, randomized study in 124 female patients. Am J Obstet Gynecol 1991; 165:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/21\">",
"      ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 74. Antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2006; 108:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/22\">",
"      Sand PK, Hill RC, Ostergard DR. Supine urethroscopic and standing cystometry as screening methods for the detection of detrusor instability. Obstet Gynecol 1987; 70:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/23\">",
"      Scotti RJ, Myers DL. A comparison of the cough stress test and single-channel cystometry with multichannel urodynamic evaluation in genuine stress incontinence. Obstet Gynecol 1993; 81:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/24\">",
"      Abrams, P, Blaivas, JG, Stanton, SL, et al. The standardization of terminology of lower urinary tract function recommended by the International Continence Society. Int Urogynecol J Pelvic Floor Dysfunct 1990; 1:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/25\">",
"      Alperin M, Abrahams-Gessel S, Wakamatsu MM. Development of de novo urge incontinence in women post sling: the role of preoperative urodynamics in assessing the risk. Neurourol Urodyn 2008; 27:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/26\">",
"      Al-Hayek S, Belal M, Abrams P. Does the patient's position influence the detection of detrusor overactivity? Neurourol Urodyn 2008; 27:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/27\">",
"      Pollak JT, Neimark M, Connor JT, Davila GW. Air-charged and microtransducer urodynamic catheters in the evaluation of urethral function. Int Urogynecol J Pelvic Floor Dysfunct 2004; 15:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/28\">",
"      Mayer, R, Wells, T, Brink, C, et al. Handwashing in the cystometric evaluation of detrusor overactivity. Neurourol Urodyn 1991; 10:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/29\">",
"      Salvatore, S, Sologo, M, Monti, C. Can we improve diagnosis on urodynamics? Neurourol Urodyn 1998; 17:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/30\">",
"      Barnick, CG, Cardozo, DL, Benness, C. Use of routine videocystourethrography in the evaluation of female lower urinary tract dysfunction. Neurourol Urodyn 1989; 8:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/31\">",
"      Artibani W. Diagnosis and significance of idiopathic overactive bladder. Urology 1997; 50:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/32\">",
"      Porru D, Usai E. Standard and extramural ambulatory urodynamic investigation for the diagnosis of detrusor instability-correlated incontinence and micturition disorders. Neurourol Urodyn 1994; 13:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/33\">",
"      Vereecken RL, Van Nuland T. Detrusor pressure in ambulatory versus standard urodynamics. Neurourol Urodyn 1998; 17:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/34\">",
"      Patravali N. Ambulatory urodynamic monitoring: are we wasting our time? J Obstet Gynaecol 2007; 27:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/35\">",
"      van Waalwijk van Doorn ES, Remmers A, Janknegt RA. Conventional and extramural ambulatory urodynamic testing of the lower urinary tract in female volunteers. J Urol 1992; 147:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/36\">",
"      Bhatia NN, Bradley WE, Haldeman S, Johnson BK. Continuous ambulatory urodynamic monitoring. Br J Urol 1982; 54:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/37\">",
"      Kulseng-Hanson, S, Klevmark, B. Ambulatory urodynamic monitoring of women. Scand J Urol Nephrol 1996; 179:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/38\">",
"      Stanton SL, Ozsoy C, Hilton P. Voiding difficulties in the female: prevalence, clinical and urodynamic review. Obstet Gynecol 1983; 61:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/39\">",
"      Bergman A, Bhatia NN. Uroflowmetry for predicting postoperative voiding difficulties in women with stress urinary incontinence. Br J Obstet Gynaecol 1985; 92:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/40\">",
"      Haylen BT, Ashby D, Sutherst JR, et al. Maximum and average urine flow rates in normal male and female populations--the Liverpool nomograms. Br J Urol 1989; 64:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/41\">",
"      Nitti VW, Raz S. Obstruction following anti-incontinence procedures: diagnosis and treatment with transvaginal urethrolysis. J Urol 1994; 152:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/42\">",
"      Defreitas GA, Zimmern PE, Lemack GE, Shariat SF. Refining diagnosis of anatomic female bladder outlet obstruction: comparison of pressure-flow study parameters in clinically obstructed women with those of normal controls. Urology 2004; 64:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/43\">",
"      Chaliha C, Digesu GA, Hutchings A, Khullar V. Changes in urethral function with bladder filling in the presence of urodynamic stress incontinence and detrusor overactivity. Am J Obstet Gynecol 2005; 192:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/44\">",
"      Rosenzweig BA, Bhatia NN, Nelson AL. Dynamic urethral pressure profilometry pressure transmission ratio: what do the numbers really mean? Obstet Gynecol 1991; 77:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/45\">",
"      Bowen LW, Sand PK, Ostergard DR, Franti CE. Unsuccessful Burch retropubic urethropexy: a case-controlled urodynamic study. Am J Obstet Gynecol 1989; 160:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/46\">",
"      Koonings PP, Bergman A, Ballard CA. Low urethral pressure and stress urinary incontinence in women: risk factor for failed retropubic surgical procedure. Urology 1990; 36:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/47\">",
"      McGuire EJ. Urodynamic findings in patients after failure of stress incontinence operations. Prog Clin Biol Res 1981; 78:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/48\">",
"      Horbach NS, Blanco JS, Ostergard DR, et al. A suburethral sling procedure with polytetrafluoroethylene for the treatment of genuine stress incontinence in patients with low urethral closure pressure. Obstet Gynecol 1988; 71:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/49\">",
"      Rezapour M, Falconer C, Ulmsten U. Tension-Free vaginal tape (TVT) in stress incontinent women with intrinsic sphincter deficiency (ISD)--a long-term follow-up. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12 Suppl 2:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/50\">",
"      Appell RA. Primary slings for everyone with genuine stress incontinence? The argument for... Int Urogynecol J Pelvic Floor Dysfunct 1998; 9:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/51\">",
"      Rud T. Urethral pressure profile in continent women from childhood to old age. Acta Obstet Gynecol Scand 1980; 59:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/52\">",
"      Rud T. The effects of estrogens and gestagens on the urethral pressure profile in urinary continent and stress incontinent women. Acta Obstet Gynecol Scand 1980; 59:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/53\">",
"      Sultana CJ. Urethral closure pressure and leak-point pressure in incontinent women. Obstet Gynecol 1995; 86:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/54\">",
"      Swift SE, Ostergard DR. A comparison of stress leak-point pressure and maximal urethral closure pressure in patients with genuine stress incontinence. Obstet Gynecol 1995; 85:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/55\">",
"      Bump RC, Elser DM, Theofrastous JP, McClish DK. Valsalva leak point pressures in women with genuine stress incontinence: reproducibility, effect of catheter caliber, and correlations with other measures of urethral resistance. Continence Program for Women Research Group. Am J Obstet Gynecol 1995; 173:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/56\">",
"      Miklos JR, Sze EH, Karram MM. A critical appraisal of the methods of measuring leak-point pressures in women with stress incontinence. Obstet Gynecol 1995; 86:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/57\">",
"      Haab F, Zimmern PE, Leach GE. Female stress urinary incontinence due to intrinsic sphincteric deficiency: recognition and management. J Urol 1996; 156:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/58\">",
"      Decter RM, Harpster L. Pitfalls in determination of leak point pressure. J Urol 1992; 148:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/59\">",
"      St&ouml;hrer M, Goepel M, Kondo A, et al. The standardization of terminology in neurogenic lower urinary tract dysfunction: with suggestions for diagnostic procedures. International Continence Society Standardization Committee. Neurourol Urodyn 1999; 18:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32120/abstract/60\">",
"      McGuire EJ, Fitzpatrick CC, Wan J, et al. Clinical assessment of urethral sphincter function. J Urol 1993; 150:1452.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8069 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B3512DFB86-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_23_32120=[""].join("\n");
var outline_f31_23_32120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CYSTOMETRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Normal observations and results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Common abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Detrusor overactivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Genuine stress incontinence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Idiopathic sensory urgency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Neurologic abnormality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Interstitial cystitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Elevated baseline pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Postprocedure care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Modifications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Videourodynamics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Ambulatory urodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      UROFLOWMETRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PRESSURE-FLOW STUDY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      URETHRAL PRESSURE PROFILE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      LEAK POINT PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      POSTVOID RESIDUAL VOLUME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      ELECTROPHYSIOLOGIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/8069\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8069|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/29/4562\" title=\"figure 1\">",
"      Urethral pressure profile",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8069|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/6/15467\" title=\"table 1\">",
"      Urodynamic testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/10/43177?source=related_link\">",
"      Stress urinary incontinence in women: Choosing a primary surgical procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44409?source=related_link\">",
"      Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_23_32121="VF sup quadrantanopia";
var content_f31_23_32121=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F69526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F69526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Visual fields: Superior quadrantanopia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 239px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Goldmann visual field showing a left superior homonymous quadrantanopia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zhang X, Kedar S, Lynn MJ, et al. Homonymous hemianopias: clinical-anatomic correlations in 904 cases. Neurology 2006; 66:906. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_23_32121=[""].join("\n");
var outline_f31_23_32121=null;
var title_f31_23_32122="Postmenopausal hormone therapy: Benefits and risks";
var content_f31_23_32122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postmenopausal hormone therapy: Benefits and risks",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/23/32122/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/23/32122/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/23/32122/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/23/32122/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/23/32122/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/23/32122/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/23/32122/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/23/32122/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/23/32122/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal women have menopause at a mean age of 51 years, with 95 percent becoming menopausal between the ages of 45 to 55 years. Estrogen is the most effective treatment available for relief of menopausal symptoms, most importantly, hot flashes. Postmenopausal hormone therapy (estrogen alone or combined with a progestin) is currently indicated for management of menopausal symptoms.",
"   </p>",
"   <p>",
"    An overview of the risks and benefits of postmenopausal hormone therapy will be provided here. The management of women with hot flashes and other menopausal symptoms is reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40615?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of menopausal symptoms with hormone therapy\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91121219\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmenopausal hormone therapy continues to play an important role in the management of hot flashes. It is highly effective for the management of hot flashes, vaginal atrophy and, in some cases, the mood lability that many women experience during the menopausal transition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/1\">",
"     1",
"    </a>",
"    ]. Details on management of vasomotor symptoms are reviewed in detail separately. The use of vaginal estrogen for vaginal atrophy is also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=see_link\">",
"     \"Treatment of vaginal atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, hormone therapy was also often prescribed for prevention of coronary heart disease (CHD) and osteoporosis, based upon epidemiologic data demonstrating a protective effect of estrogen on the heart and bone. However, data from the Women's Health Initiative (WHI), a set of two hormone therapy trials (unopposed estrogen and continuous, combined estrogen-progestin therapy versus placebo), in healthy postmenopausal women (mean age 63 years) showed a number of adverse outcomes, including an excess risk of CHD, stroke, venous thromboembolism, and breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar results were noted in a meta-analysis of 23 trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/4\">",
"     4",
"    </a>",
"    ], and an updated 2012 United States Preventive Services Task Force (USPSTF) meta-analysis of nine trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/5\">",
"     5",
"    </a>",
"    ]. Both included the WHI, and the mean age of subjects was &gt;60 years. In the USPSTF analysis, results were largely based upon the WHI. Based upon their current meta-analysis, the USPSTF continues to recommend against the use of both combined estrogen and progestin and unopposed estrogen (for women post-hysterectomy) for the prevention of chronic conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, they note that this recommendation does not apply to women considering using hormone therapy for relief of menopausal symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the WHI clearly demonstrated the adverse effects of hormone therapy in older postmenopausal women (over age 60), this is not the age group that presents with new onset of menopausal symptoms. Almost all women who seek medical therapy for menopausal symptoms do so in their late 40s or 50s. Most experts suggest that combined therapy be limited to five years of use (because of an increased risk of breast cancer). However, there may be more flexibility in duration of use with unopposed estrogen (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Breast cancer'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    When counseling women about postmenopausal hormone therapy, the clinician should provide estimates for the absolute risks and benefits for up to five years of treatment in young postmenopausal women (eg, &lt;10 years postmenopausal, or ages 50 to 59 years). Women should be reassured that the absolute risk of complications for healthy, young postmenopausal women taking hormone therapy for five years is very low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H507693\">",
"    <span class=\"h1\">",
"     ESTIMATES OF RISK IN WOMEN 50 TO 59",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women who seek hormone therapy for menopausal symptoms are in their late 40s or early 50s, and current guidelines suggest that hormone therapy be used only short-term for symptom relief (up to five years). When counseling symptomatic women considering hormone therapy, the clinician should provide the best estimate of potential risks and benefits for five years of use based upon data from women in their 50s.",
"   </p>",
"   <p>",
"    Although most available hormone therapy clinical trial data is from women over age 60 years, estimates of the absolute risks and benefits for women starting menopausal hormone therapy in their 50s has been published (",
"    <a class=\"graphic graphic_figure graphicRef87938 \" href=\"mobipreview.htm?36/2/36911\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/8\">",
"     8",
"    </a>",
"    ]. The WHI was the major source of data for the analysis, although other studies were used as well. Of note, these estimates are based upon low quality evidence because both the number of subjects and events in women ages 50 to 59 in the WHI was small.",
"   </p>",
"   <p>",
"    Data was expressed as the attributable excess risk or benefit for five years of combined E+P or unopposed E use in women starting treatment between ages 50 to 59 (or &lt;10 years postmenopause) (",
"    <a class=\"graphic graphic_figure graphicRef87938 \" href=\"mobipreview.htm?36/2/36911\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H507700\">",
"    <span class=\"h2\">",
"     Benefit or no effect",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary heart disease: 0.9 and 3.8 fewer cases per 1000 women per five years of E+P and E use, respectively",
"     </li>",
"     <li>",
"      Mortality: 5.3 and 5 fewer deaths per 1000 women per five years of E+P and E use, respectively",
"     </li>",
"     <li>",
"      Fracture: 4.9 and 5.9 fewer cases per 1000 women per five years of E+P and E use, respectively",
"     </li>",
"     <li>",
"      Breast cancer: 1.5 fewer cases per 1000 women per five years of unopposed estrogen use (WHI hazard ratios of breast cancer risk not used for this estimate as they were thought to be considerably lower compared with most previous reports; authors used data from Nurses&rsquo; Health Study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/9\">",
"       9",
"      </a>",
"      ]. A slight reduction in risk was still seen)",
"     </li>",
"     <li>",
"      Type 2 diabetes: 11 fewer cases per 1000 women per five years (for E+P and E use combined)",
"     </li>",
"     <li>",
"      Colorectal cancer: 1.2 fewer cases per 1000 women per five years of use for E+P only",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H507707\">",
"    <span class=\"h2\">",
"     Risk",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stroke: 1.0 and 1.2 additional cases per 1000 women per five years of E+P and E use, respectively",
"     </li>",
"     <li>",
"      Venous thromboembolism (VTE): 5 and 2 additional cases per 1000 women per five years of E+P and E use, respectively",
"     </li>",
"     <li>",
"      Breast cancer: 6.8 additional cases per 1000 women per five years of E+P (WHI hazard ratios of breast cancer risk not used for this estimate as they were thought to be considerably lower compared with most previous reports; authors used data from Nurses&rsquo; Health Study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/9\">",
"       9",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Cholecystitis: 9.6 and 14.2 additional cases per 1000 women per five years of E+P and E use, respectively (data from women of",
"      <strong>",
"       all",
"      </strong>",
"      ages in WHI used for calculation; no data available for women 50 to 59)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This analysis highlights that the overall risks of hormone therapy in younger postmenopausal women are considerably lower than those for older women (eg, women in the WHI). The major explanation for the difference in absolute excess risk between older and younger postmenopausal women is the lower baseline risk of CHD, stroke, VTE, and breast cancer in younger postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178089454\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Women's Health Initiative (WHI) reported that many of the apparent benefits of postmenopausal hormone therapy seen in epidemiologic studies were not found in the randomized trials. Rather than a reduction in risk of CHD events, an increase was seen. Possible methodologic explanations for the striking difference in CHD data include \"healthy user\" bias, older age of the study population, and timing of initiation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link&amp;anchor=H9#H9\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Timing of exposure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41975?source=see_link\">",
"     \"Estrogen and cognitive function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178089461\">",
"    <span class=\"h2\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall rate of coronary events was increased with combined CEE-MPA therapy (+eight additional events per 10,000 person-years, respectively; hazard ratio [HR] 1.23, 95% CI -0.3-16.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link&amp;anchor=H2#H2\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Coronary heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the unopposed estrogen trial, use of CEE did not appear to affect the incidence of CHD events over an average follow-up of 6.8 years (HR for CEE versus placebo 0.96, 95% CI 0.78-1.16 [three fewer events per 10,000 person years]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/3,12\">",
"     3,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Younger postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from a coronary angiographic study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/14\">",
"     14",
"    </a>",
"    ], a WHI coronary artery calcification study and age-based subgroup analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/12,15\">",
"     12,15",
"    </a>",
"    ], and a meta-analysis that included the WHI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/16\">",
"     16",
"    </a>",
"    ] all suggest that the timing of treatment initiation affects the risk of CHD; in the WHI, women who were &lt;10 years since menopause or between the ages of 50 to 59 years did not have excess risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/12\">",
"     12",
"    </a>",
"    ], or possibly had a reduction in risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link&amp;anchor=H9#H9\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Timing of exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional reassuring data come from clinical trial data in younger postmenopausal women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The KEEPS study (Kronos Early Estrogen Prevention Study), a four-year, randomized, double-blind, placebo-controlled trial (in women ages 45 to 54 years) reported that when combined with cyclical monthly oral progesterone, oral conjugated estrogen (0.45 mg daily) or transdermal estrogen (50 mcg daily) reduced menopausal symptoms. Surrogate markers of atherosclerosis (coronary artery calcium and carotid intima-medial thickness) were not significantly different in the hormone therapy and placebo groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subgroup analysis of a 10-year postmenopausal hormone therapy trial for osteoporosis reported that women taking hormone therapy had a reduced risk of the composite outcome of mortality, heart failure, or myocardial infarction, without an increased risk of stroke, venous thromboembolism or cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/19\">",
"       19",
"      </a>",
"      ]. However, there are methodologic concerns about this study, including lack of placebo group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/20\">",
"       20",
"      </a>",
"      ], and use of a composite outcome that was not described in the original study protocol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Estimates of the risks and benefits for younger postmenopausal women taking five years of hormone therapy are described above (see",
"    <a class=\"local\" href=\"#H507693\">",
"     'Estimates of risk in women 50 to 59'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the WHI, a 31 percent increase in stroke risk was seen with combined CEE-MPA use compared with placebo (intention-to-treat HR 1.31, 95% CI 1.02-1.68). The increase in risk is for ischemic but not hemorrhagic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/22\">",
"     22",
"    </a>",
"    ]. Excess risk was seen in all age groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/12\">",
"     12",
"    </a>",
"    ] and was independent of other known risk factors for stroke. In the unopposed estrogen trial, stroke risk was significantly increased with CEE versus placebo (HR 1.39, HR 1.1 to 1.77) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a subgroup analysis that combined data from both trials, the relative risk of stroke did not vary by patient age. However, the authors calculated an extremely low absolute excess risk of stroke in women ages 50 to 59 years (0.15 versus 0.13 cases per 100 women per year for hormone therapy and placebo, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stroke risk appears to be lower with transdermal compared with oral estrogen preparations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link&amp;anchor=H15#H15\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Estimates of the risks and benefits for younger postmenopausal women taking five years of hormone therapy are described above (see",
"    <a class=\"local\" href=\"#H507693\">",
"     'Estimates of risk in women 50 to 59'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of venous thromboembolism (VTE) in the WHI increased with combined CEE-MPA therapy (34 versus 16 per 10,000 person-years, HR 2.06, unadjusted 95% CI 1.6-2.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/23\">",
"     23",
"    </a>",
"    ]. The increase in risk was similar for both deep vein thrombosis (DVT) and pulmonary embolism (PE) and was also seen in the HERS trials.",
"   </p>",
"   <p>",
"    VTE risk was also increased with unopposed CEE when compared with placebo (HR 1.33, 95% CI 0.99-1.79) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/3\">",
"     3",
"    </a>",
"    ]. However, only the increased rate of DVT reached statistical significance.",
"   </p>",
"   <p>",
"    For women ages 50 to 59, the group most likely to be taking hormone therapy, the estimates of excess venous thromboembolism risk in one analysis were 4.7 and 1.3 additional cases per 1000 women per five years of combined estrogen-progestin or unopposed estrogen use, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H507693\">",
"     'Estimates of risk in women 50 to 59'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The risk of venous thromboembolism appears to be lower with transdermal compared with oral estrogen preparations. In addition, risk may vary by type of progestin (higher with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    ). This issue is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link&amp;anchor=H18#H18\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Venous thromboembolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91122874\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the WHI and HERS trials, there were no differences in total mortality between the hormone therapy and placebo groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/2,3,24\">",
"     2,3,24",
"    </a>",
"    ]. However, when the WHI was reanalyzed by patient age, a significant 30 percent mortality reduction was seen in women under 60 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For women ages 50 to 59, the group most likely to be taking hormone therapy, the estimate of mortality benefit in one analysis was 5.3 and 5 fewer deaths per 1000 per five years of combined estrogen-progestin or unopposed estrogen use, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H507693\">",
"     'Estimates of risk in women 50 to 59'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other evidence for the effect of hormone therapy on mortality comes from a metaanalysis of 19 randomized, controlled trials in younger postmenopausal women, including age-specific data (women 50 to 59 years) from the two WHI trials, and 17 trials with a mean subject age &lt;60 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/25\">",
"     25",
"    </a>",
"    ]. In the pooled analysis of approximately 16,000 women (mean age 55 years) followed for an average of 5.1 years, hormone therapy reduced mortality by 27 percent when compared with placebo (RR 0.73; 95% 0.52-0.96). The absolute reduction in mortality was 0.84 percent (ie, 1 in every 119 women treated with hormone therapy did not die at five years compared with untreated patients).",
"   </p>",
"   <p>",
"    These data provide additional reassurance that hormone therapy is a safe option for the treatment of symptoms in younger postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H507693\">",
"     'Estimates of risk in women 50 to 59'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256689819\">",
"    <span class=\"h1\">",
"     CANCER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the WHI, the risk of invasive breast cancer was significantly increased with combined hormone therapy at an average follow-up of 5.6 years (HR 1.24, unadjusted 95% CI 1.01-1.54) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/27\">",
"     27",
"    </a>",
"    ]. It has been suggested that the breast cancers that develop in women taking estrogen have a relatively favorable prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/28\">",
"     28",
"    </a>",
"    ]. However, in the WHI, estrogen-progestin therapy was associated with slightly larger primary cancers at the time of diagnosis and a higher percentage of women with positive lymph nodes when compared with placebo.",
"   </p>",
"   <p>",
"    In contrast to the results of the combined hormone therapy trial, a trend towards a slightly lower rate of breast cancer risk was seen in the unopposed estrogen trial (HR 0.77 for unopposed estrogen versus placebo, 95% CI 0.59-1.01) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/3\">",
"     3",
"    </a>",
"    ]. This comparison narrowly missed statistical significance (p = 0.06). Other issues including mammographic density, breast cancer prognosis, use of hormone therapy in breast cancer survivors, and the impact of time since menopause on risk (&ldquo;gap time&rdquo;) are all reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Estimates of the risks and benefits for younger postmenopausal women taking five years of hormone therapy are described above (see",
"    <a class=\"local\" href=\"#H507693\">",
"     'Estimates of risk in women 50 to 59'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256689856\">",
"    <span class=\"h2\">",
"     Ovarian cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nonsignificant increase in the risk of ovarian cancer was observed in the WHI with combined estrogen-progestin therapy (HR 1.6, 95% CI 0.8-3.2; 42 versus 27 cases per 100,000 person-years in the hormone and placebo groups, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/29\">",
"     29",
"    </a>",
"    ]. The excess risk was not statistically significant and would be approximately 0.75 cases per 1000 women treated for five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There were no differences in the distributions of tumor grade, stage, or histology. Because of the small number of ovarian cancer cases and the limited precision in estimating effects in the trial, the authors concluded that these results should not affect a woman's decision to take HT for symptomatic relief.",
"   </p>",
"   <p>",
"    Observational data, including a meta-analysis of studies (mostly case-control studies) found a small but significant increase in the relative risk of ovarian cancer (relative risk 1.27) in postmenopausal women who had taken estrogen for more than 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/30\">",
"     30",
"    </a>",
"    ]. Similar results were reported in a second meta-analysis that included studies up until 2007 (eight cohort studies [n = 4715 cases] and 19 case-control studies [n = 8240 cases]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one case-control study of 162 matched sets of women with BRCA1 or BRCA2 mutations, postmenopausal hormone therapy did not appear to increase the risk of ovarian cancer; odds ratio with every use of HT was 0.93 (95% CI 0.56-1.56) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not consider ovarian cancer to be the major consideration in deciding whether to take short-term hormone therapy for menopausal symptoms because the absolute risk of ovarian cancer with estrogen therapy is small. Other risk factors for ovarian cancer are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256690677\">",
"    <span class=\"h2\">",
"     Endometrial hyperplasia and carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of postmenopausal women with estrogen alone increases the risk of endometrial hyperplasia and carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/33\">",
"     33",
"    </a>",
"    ]. Within one year, endometrial hyperplasia can be demonstrated in 20 to 50 percent of women receiving unopposed estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Furthermore, multiple case-control and prospective studies have shown an increased incidence of endometrial carcinoma with long-term unopposed estrogen, with the relative risk ranging from 3.1 to 15 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. A meta-analysis of clinical trials of hormone therapy and endometrial hyperplasia risk is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=see_link&amp;anchor=H7#H7\">",
"     \"Classification and diagnosis of endometrial hyperplasia\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the absolute risk of endometrial carcinoma in postmenopausal women is about 1 in 1000, then the absolute risk in women taking unopposed estrogen increases to approximately 1 in 100 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/36\">",
"     36",
"    </a>",
"    ]. While the risk of both localized and widespread endometrial cancer is increased with long-term unopposed estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/40\">",
"     40",
"    </a>",
"    ], the tumors that develop may be less aggressive, as survival is better in women with cancers associated with estrogen therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of endometrial hyperplasia and cancer with unopposed estrogen therapy is both duration- and dose-dependent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the relative risk of endometrial cancer increased by 17 percent per year of estrogen therapy, to an odds ratio of greater than 8 after 10 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/38\">",
"       38",
"      </a>",
"      ]. The excess risk persisted five or more years after cessation of therapy.",
"     </li>",
"     <li>",
"      In a dose-response study, lower doses of estrogen (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/39/29303?source=see_link\">",
"       esterified estrogens",
"      </a>",
"      0.3 mg daily) for two years did not increase the incidence of endometrial hyperplasia compared with no estrogen (1.7 percent in both groups), while doses of 0.625 and 1.25 mg were associated with higher rates of disease, 28 and 53 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/41\">",
"       41",
"      </a>",
"      ]. However, when a low-dose (0.3 mg per day of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/23/35184?source=see_link\">",
"       conjugated equine estrogens",
"      </a>",
"      ) was given for longer than eight years, there was a ninefold increased risk of endometrial cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/42\">",
"       42",
"      </a>",
"      ]. The risk of endometrial hyperplasia was not determined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Equivalent doses of transdermal and oral estrogen appear to have similar effects on the endometrium. Ultra-low dose transdermal estrogen and placebo result in similarly low rates of endometrial proliferation and endometrial hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of endometrial hyperplasia with unopposed estrogen is not reduced by giving it in a cyclic regimen. In one study, for example, in which 25 women were randomly assigned to receive either continuous or cyclic estrogen therapy (without progestin) and followed with serial endometrial biopsies, the incidence of endometrial hyperplasia was almost 50 percent in both groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256690730\">",
"    <span class=\"h3\">",
"     Protective effect of progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the WHI, among women treated with estrogen, the excess risk of endometrial hyperplasia and carcinoma can be largely abolished by concurrent therapy with a progestin given in either a cyclic or continuous regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/29,34,44-46\">",
"     29,34,44-46",
"    </a>",
"    ]. In the estrogen-progestin WHI trial, more women in the hormone therapy group required endometrial biopsies to assess vaginal bleeding (33 versus 6 percent for placebo), but there was no significant difference in endometrial cancer risk between the two groups (HR 0.81, 95% CI 0.48-1.36) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the PEPI trial, for example, combined estrogen-progestin therapy led to marked reductions in the incidence of simple (0.8 versus 27.7 percent), complex (0.8 versus 23.7 percent), and atypical hyperplastic (0 versus 11.8 percent) endometrial lesions when compared with unopposed estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the PEPI trial and in a review from the Cochrane Database, cyclic progestin (when given at least 12 days per month) was as effective as continuous low-dose progestin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/4,45\">",
"     4,45",
"    </a>",
"    ]. Shorter duration progestin therapy (&lt;10 to 12 days) may be less protective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/4,38,47-50\">",
"     4,38,47-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=see_link&amp;anchor=H7#H7\">",
"     \"Classification and diagnosis of endometrial hyperplasia\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In another report, cyclic monthly users of estrogen-progestin had a higher risk of endometrial cancer than continuous estrogen-progestin users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A commonly used combined continuous estrogen-progestin regimen in the United States is low-dose medroxyprogesterone (2.5 or 5 mg daily) given each day with estrogen (conjugated estrogens 0.625 mg or its equivalent). This regimen is associated with a low risk of endometrial hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/29,34,52\">",
"     29,34,52",
"    </a>",
"    ], and has the added advantage of inducing amenorrhea in 60 to 75 percent of women after more than six months of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/34/40486?source=see_link\">",
"     \"Continuous postmenopausal hormone therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other estrogen-progestin regimens that have been investigated include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral micronized progesterone (200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for 12 days) reduces the risk of hyperplasia to the same degree as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      continuously or 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for 12 days) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/45,55\">",
"       45,55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medroxyprogesterone (10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for 14 days every three months may be associated with higher than normal rates of endometrial hyperplasia and cannot be recommended [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/48,56,57\">",
"       48,56,57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lower doses of combined estrogen-progestin therapy (conjugated estrogen [0.3 or 0.45",
"      <span class=\"nowrap\">",
"       mg/day]",
"      </span>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      [1.5 or 2.5",
"      <span class=\"nowrap\">",
"       mg/day])",
"      </span>",
"      also appear to be endometrial protective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Levonorgestrel-releasing intrauterine systems (LNG-IUS) are contraceptive agents that have been used off-label for endometrial protection by some peri- and postmenopausal women taking estrogen. The strategy is to avoid the potential excess risk of cardiovascular disease and breast cancer associated with systemic progestins such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=see_link&amp;anchor=H23#H23\">",
"       \"Preparations for postmenopausal hormone therapy\", section on 'Intrauterine device'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256690737\">",
"    <span class=\"h3\">",
"     Endometrial polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that postmenopausal hormone therapy may be associated with an increased risk of endometrial polyps. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7336?source=see_link&amp;anchor=H348860#H348860\">",
"     \"Endometrial polyps\", section on 'Other risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the WHI, the risk of colorectal cancer was reduced with combined CEE-MPA use (43 cases versus 72 in the hormone and placebo groups, respectively; HR 0.56, 95% CI 0.38-0.81) (",
"    <a class=\"graphic graphic_figure graphicRef75354 \" href=\"mobipreview.htm?14/11/14525\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/59\">",
"     59",
"    </a>",
"    ]. This risk reduction is similar to that seen in epidemiologic studies. In contrast to the results of combined hormone therapy,",
"    <strong>",
"     no",
"    </strong>",
"    significant differences were found in rates of colorectal cancer for unopposed CEE versus placebo use (HR 1.08, 95% CI 0.75-1.55) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/3\">",
"     3",
"    </a>",
"    ]. This topic is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link&amp;anchor=H28#H28\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Postmenopausal hormone therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256690015\">",
"    <span class=\"h2\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women on combined estrogen-progestin therapy who developed non-small cell lung cancer (NSCLC) had a significantly shorter survival compared with those given placebo. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10072?source=see_link&amp;anchor=H10#H10\">",
"     \"Women and lung cancer\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H438948986\">",
"    <span class=\"h1\">",
"     COGNITIVE FUNCTION AND DEMENTIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some epidemiologic studies suggested that estrogen may preserve cognitive function and prevent dementia, data from the WHI (in women over age 65 years) do not support these observations. The WHI Memory Study (WHIMS), an ancillary study of the WHI, assessed annual cognitive function scores in 4532 postmenopausal women who were over age 65 and free of probable dementia at baseline.",
"   </p>",
"   <p>",
"    Both unopposed estrogen and combined estrogen-progestin therapy had no global cognitive benefits in older, non-demented postmenopausal women and led to accelerated cognitive decline. In addition, neither type of hormone therapy prevented dementia in older, non-demented postmenopausal women; to the contrary, it increased risk.",
"   </p>",
"   <p>",
"    In contrast to the WHI results, some, but not all, epidemiologic studies suggest that women who initiate hormone therapy soon after menopause have a decreased risk of later dementia, while women who start many years after menopause do not. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41975?source=see_link&amp;anchor=H14#H14\">",
"     \"Estrogen and cognitive function\", section on 'Timing of exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H438948993\">",
"    <span class=\"h1\">",
"     GALLBLADDER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A secondary analysis of data from the WHI found a significantly increased risk of biliary tract disease among women using oral estrogen therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/60\">",
"     60",
"    </a>",
"    ]. Both trials showed a greater risk of any gallbladder disease or surgery in the groups randomized to oral estrogen (hazard ratios [HR] of 1.67 and 1.59 in the estrogen alone and estrogen plus progestin studies, respectively). Women receiving estrogen were more likely to experience an episode of cholecystitis (HR of 1.80 and 1.54, respectively) and were more likely to undergo cholecystectomy (HR of 1.93 and 1.67, respectively).",
"   </p>",
"   <p>",
"    Similar results were noted in the HERS trial, in which 2763 postmenopausal women with CHD were randomly assigned to combined estrogen-progestin therapy or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/61\">",
"     61",
"    </a>",
"    ]. After an average follow-up of four years, there was a marginally significant increase in biliary tract surgery in the treatment group (38 percent). The authors calculated that for every 185 women receiving HT, one additional woman had biliary tract surgery per year. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4489?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology of and risk factors for gallstones\", section on 'Oral contraceptives and estrogen replacement therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one analysis of the WHI, the attributable excess risk of cholecystitis was calculated to be 9.6 and 14.2 additional cases per 1000 women per five years of combined estrogen-progestin therapy or unopposed estrogen use, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256689942\">",
"    <span class=\"h1\">",
"     OSTEOPOROTIC FRACTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of osteoporotic fracture with combined hormone therapy versus placebo was reduced at the hip (HR 0.67, unadjusted 95% CI 0.47-0.96) and at the vertebrae and wrist (HR 0.65, unadjusted 95% CI 0.46-0.92; and HR 0.71, 95% CI 0.59-0.85, respectively) (",
"    <a class=\"graphic graphic_figure graphicRef55425 \" href=\"mobipreview.htm?15/44/16077\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/62\">",
"     62",
"    </a>",
"    ]. Similar risk reductions were seen with unopposed CEE for hip fracture (HR 0.61, 95% CI 0.41-0.91) and vertebral fracture (HR 0.62, 95% CI 0.42-0.93) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17831?source=see_link\">",
"     \"Postmenopausal hormone therapy in the prevention and treatment of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women ages 50 to 59, the group most likely to be taking hormone therapy, the estimates of benefit in one analysis were 4.9 and 5.9 fewer fractures per 1000 women per five years of combined estrogen-progestin or unopposed estrogen use, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H507693\">",
"     'Estimates of risk in women 50 to 59'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     TYPE 2 DIABETES MELLITUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a post-hoc analysis from the HERS trial, a secondary prevention of CHD study, 734 of 2783 women were diabetic at baseline; the remaining 2029 women (who were normoglycemic or had impaired glucose tolerance) were followed for the development of type 2 diabetes for an average of four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/63\">",
"     63",
"    </a>",
"    ]. Results of the trial were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cumulative incidence of type 2 diabetes was 6.2 percent in the HT group compared with 9.5 percent in the placebo group (RH 0.65; 95% CI 0.48-0.89).",
"     </li>",
"     <li>",
"      Results were still significant after adjustment for variables such as body mass index, weight change, and waist circumference.",
"     </li>",
"     <li>",
"      The number needed to treat to prevent one case of diabetes was 30 (CI 18-103).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results were reported in the WHI combined estrogen-progestin trial in which fasting glucose and insulin were measured in a random sample at baseline and at one and three years. After a mean follow-up of 5.6 years the following results were seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cumulative incidence of treated diabetes was 3.5 percent in the hormone group and 4.2 percent in the placebo group (HR 0.79, 95% CI 0.7-0.9). There was little change in the hazard ratio after adjustment for changes in BMI and waist circumference.",
"     </li>",
"     <li>",
"      Changes in fasting glucose and insulin during the first year of follow-up suggested a decrease in insulin resistance in the hormone group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, combined HT appears to reduce the risk of type 2 diabetes mellitus, possibly mediated by a decrease in insulin resistance unrelated to body size. However, this effect is insufficient to recommend HT as a diabetes prevention strategy in women with CHD.",
"   </p>",
"   <p>",
"    For women ages 50 to 59, the group most likely to be taking hormone therapy, the estimate of benefit in one analysis was 11 fewer cases per 1000 per five years of use (for E+P and E use combined) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H507693\">",
"     'Estimates of risk in women 50 to 59'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91121403\">",
"    <span class=\"h1\">",
"     OTHER POSSIBLE BENEFITS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Recurrent urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen therapy, in particular, vaginal estrogen, is effective for the symptoms of vaginal atrophy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of vaginal atrophy\", section on 'Vaginal estrogen therapy'",
"    </a>",
"    .) Estrogen may also be beneficial for reducing the frequency of recurrent urinary tract infections in postmenopausal women, but the effect appears to be specific to vaginal estrogen, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized, controlled trial found that vaginal estrogen decreased the risk of recurrence in patients with frequent urinary tract infections (0.5 versus 5.9 episodes per patient-year) (",
"      <a class=\"graphic graphic_figure graphicRef79118 \" href=\"mobipreview.htm?20/31/20989\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/65\">",
"       65",
"      </a>",
"      ]. This benefit may be due to normalization of the vaginal flora since the patients treated with estrogen cream had an increase in the prevalence of lactobacilli and decrease in E. coli vaginal colonization.",
"     </li>",
"     <li>",
"      In a meta-analysis of five estrogen trials (three using the vaginal route of administration and two using the oral route) in 334 postmenopausal women, estrogen therapy significantly reduced the rate of urinary tract infection when compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/66\">",
"       66",
"      </a>",
"      ]. However, when the trials of oral and vaginal estrogen were analyzed separately, vaginal estrogen was beneficial, while oral estrogen was not.",
"     </li>",
"     <li>",
"      In the Heart and",
"      <span class=\"nowrap\">",
"       Estrogen/Progestin",
"      </span>",
"      Replacement Study (HERS), a four-year study of 2763 postmenopausal women, the frequency of urinary tract infections was not decreased in those receiving oral estrogen-progestin therapy compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, there is some evidence that vaginal, but not systemic, estrogen therapy may reduce the frequency of recurrent urinary tract infections in postmenopausal women. It has been suggested that vaginal estrogen may be reasonable in postmenopausal women not taking oral estrogen who have three or more recurrent urinary tract infections per year, particularly when antimicrobial resistance to multiple drugs limits the efficacy of antimicrobial prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5514?source=see_link\">",
"     \"Recurrent urinary tract infection in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Health-related quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen has a variable effect on quality of life in postmenopausal women, depending on the woman's age and the presence of symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    comorbid conditions. In postmenopausal women with vasomotor flushes, estrogen appears to improve quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the HERS trial, the majority of women did not have vasomotor symptoms at baseline (84.3 percent). In this group, there were greater declines in physical function and energy with estrogen therapy than placebo, while there were no changes in mental health or depressive symptoms in either group. In contrast, in the women with symptoms at baseline, estrogen improved mental health and reduced depressive symptoms, with no effect on physical function or energy level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that the decline in physical function in the asymptomatic group could be due to the increased rates of cardiovascular events in the first two years of the study. In a second study of elderly women, three years of estrogen therapy, with or without progestin, did not prevent the normal age-related decline in physical functioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the WHI (an older, asymptomatic population), no significant improvements were seen in quality of life measures (including general health, vitality, mental health, depressive symptoms, and sexual satisfaction) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/74\">",
"     74",
"    </a>",
"    ]. The WHI was not designed to examine the effects of HT on vasomotor flushes or other menopausal symptoms. However, 12 percent of the study population did have significant symptoms. In these younger women, HT relieved vasomotor flushes and improved sleep, but did not otherwise improve quality of life. In the unopposed estrogen trial, women with moderate-to-severe vasomotor symptoms at baseline experienced significant improvement in vasomotor flushes when compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/75\">",
"     75",
"    </a>",
"    ]. In the group as a whole, a minimal improvement in sleep disturbance symptoms was seen, but there were no differences in other quality of life measures (physical and social functioning, vitality, bodily pain, depressive symptoms, and sexual satisfaction) between the estrogen and placebo groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Falls",
"    </span>",
"    &nbsp;&mdash;&nbsp;Problems with balance may play a major role in the incidence of forearm fractures in postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/76\">",
"     76",
"    </a>",
"    ]. The incidence of Colles' fractures increases markedly in women at age 50 but remains stable in men up to the age of 80. A mechanism other than osteoporosis must be invoked to explain this observation because osteoporosis occurs gradually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/77\">",
"     77",
"    </a>",
"    ]. The fracture is usually caused by falling on an outstretched hand.",
"   </p>",
"   <p>",
"    Estrogen therapy may improve balance and reduce the tendency to fall, a change that could contribute to the associated decrease in fracture risk. Some studies have noted an improvement in balance with estrogen therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/78\">",
"     78",
"    </a>",
"    ], while others have not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. In one study of 19 postmenopausal women with vasomotor symptoms, for example, dynamic posturography revealed that the women had improved balance during treatment with estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17831?source=see_link\">",
"     \"Postmenopausal hormone therapy in the prevention and treatment of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen is widely thought to preserve the thickness and the collagen content of skin in postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/81-84\">",
"     81-84",
"    </a>",
"    ], but clinical trial data to support this concept are lacking. In a single-blinded cross-sectional analysis of nine long-term hormone therapy (HT) users and 11 nonusers, the HT users had more elastic skin and less severe wrinkling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/85\">",
"     85",
"    </a>",
"    ]. In contrast, a seven-month trial of estrogen-progestin therapy versus placebo in 40 postmenopausal women reported that skin elasticity and thickness were significantly improved in the HT group when compared with baseline, but there were no differences between the HT and placebo groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/86\">",
"     86",
"    </a>",
"    ]. A second six-month randomized trial in 485 women also found no differences between hormone therapy and placebo on age-related skin changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although some epidemiologic studies have suggested that postmenopausal hormone therapy is associated with an increased risk of melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/88,89\">",
"     88,89",
"    </a>",
"    ], no excess risk of either melanoma or nonmelanoma skin cancer was observed in a post-hoc analysis of the Women&rsquo;s Health Initiative (for unopposed estrogen or combined estrogen-progestin therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been thought that estrogen may reduce the risk of",
"    <strong>",
"     osteoarthritis",
"    </strong>",
"    . In a cross-sectional study of over 4000 women, those receiving long-term estrogen therapy (&ge;10 years) had a 40 percent lower risk of hip osteoarthritis than those who had not received estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/91\">",
"     91",
"    </a>",
"    ]. Similar results were found in a prospective analysis of the Framingham cohort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/92\">",
"     92",
"    </a>",
"    ]. In the Women&rsquo;s Health Initiative, women who took unopposed estrogen had lower rates of subsequent arthroplasty when compared with those taking placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, estrogen preserves",
"    <strong>",
"     teeth",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]; the relative risk for edentia was only 0.6 in postmenopausal women taking estrogen as compared with those who did not, perhaps related to less osteoporosis of the jaw [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of cataract formation appears to be decreased by long-term estrogen therapy. In the Framingham Heart Study, postmenopausal women who had taken estrogen for 10 years or longer had a 60 percent reduction in risk of nuclear lens opacities compared with control women (odds ratio 0.4; 95% CI 0.2-1.01) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/96\">",
"     96",
"    </a>",
"    ]. In a second study, subcapsular as well as nuclear opacities were decreased by 70 and 80 percent, respectively, in women taking estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=see_link\">",
"     \"Cataract in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     OTHER POSSIBLE RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen therapy may be associated with increases in the incidence of gallbladder disease, bronchospasm, ovarian cancer, systemic lupus erythematosus, and the Raynaud phenomenon. The data are insufficient for epilepsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Urinary incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen may alleviate dyspareunia, recurrent cystitis, and",
"    <span class=\"nowrap\">",
"     vaginal/urethral",
"    </span>",
"    atrophy and inflammation in postmenopausal women. However, both the HERS and WHI trials have reported that oral hormone therapy worsens incontinence. Thus, oral estrogen with or without progestin should not be prescribed for this indication. Of note, extremely low doses of unopposed transdermal estrogen (0.014",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    do not appear to increase the risk of urinary incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/98\">",
"     98",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of topical vaginal estrogen therapy for urogenital atrophy symptoms is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=see_link\">",
"     \"Treatment of vaginal atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Bronchospasm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen therapy may be associated with the onset of asthma. In the Nurses' Health Study, for example, the relative risk of new-onset asthma in 36,094 postmenopausal women followed for 10 years was significantly greater in women taking estrogen as compared with those who were not (relative risk 1.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/99\">",
"     99",
"    </a>",
"    ]. This increased risk was dose-related; it was statistically significant only at a dose greater than 0.625",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of conjugated estrogens, probably because of the small numbers of women studied.",
"   </p>",
"   <p>",
"    Data are conflicting on whether estrogen therapy in postmenopausal asthmatic women causes a worsening of airway function. In one study of 15 postmenopausal women with mild to moderate asthma, the estrogen-treated women had subclinical worsening of disease activity (as measured by peak expiratory flow and spirometry) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/100\">",
"     100",
"    </a>",
"    ]. In contrast, in a second study of 20 postmenopausal asthmatic women there were no differences in measures of airway obstruction after stopping and restarting estrogen therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, while estrogen is not contraindicated in women with obstructive lung disease, clinicians should be aware of the possibility of worsening bronchospasm. Furthermore, estrogen may be considered as an etiologic factor in women who develop asthma during therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen appears to increase the risk of developing systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/102\">",
"     102",
"    </a>",
"    ]. A report from the Nurses' Health Study found a relative risk of 2.5 for current estrogen therapy and a nonsignificant risk of 1.8 for past estrogen therapy compared with women who had never received estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/103\">",
"     103",
"    </a>",
"    ]. The risk was related to the duration of estrogen therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/43/37562?source=see_link\">",
"     \"Epidemiology and pathogenesis of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postmenopausal estrogen use may increase the risk of flare in women with established lupus, but these flares tend to be mild-to-moderate, not severe. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16646?source=see_link&amp;anchor=H4#H4\">",
"     \"Menstrual function, menopause, and hormonal contraceptives in women with systemic lupus erythematosus\", section on 'Menopause'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Uterine leiomyomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of postmenopausal hormone therapy in the post-reproductive years may cause some women with leiomyomas to continue to have symptoms after menopause. The risk of symptoms may depend, in part, on the location of the fibroid (higher if submucosal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/104\">",
"     104",
"    </a>",
"    ]) and type of estrogen preparation (higher with transdermal estrogen in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/105,106\">",
"     105,106",
"    </a>",
"    ] but not others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/107\">",
"     107",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    A systematic review including five randomized controlled trials found that postmenopausal hormone therapy caused myoma growth, but this typically occurred without clinical symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/108\">",
"     108",
"    </a>",
"    ]. These findings were confirmed in a subsequent prospective study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/109\">",
"     109",
"    </a>",
"    ]. Thus, presence of leiomyomas is not a contraindication to postmenopausal hormone therapy nor associated with new symptomatic fibroids in most women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a report of 42 menopausal women with epilepsy, HT was associated with an increase in seizure frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/110\">",
"     110",
"    </a>",
"    ]. Although these data are",
"    <strong>",
"     not",
"    </strong>",
"    sufficient to recommend that women with seizures not be offered HT, the indications for hormone replacement have diminished substantially since publication of the WHI. Women with seizures who are treated should be monitored carefully.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Dry eye syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large observational study demonstrated an increased risk of dry eye syndrome in postmenopausal women on unopposed estrogen or combined estrogen-progestin therapy compared with nonusers (RR 1.69 and 1.29; 95% CI 1.49-1.91 and 1.13-1.48, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/111\">",
"     111",
"    </a>",
"    ]. This may reflect an effect of estrogen on the tear film. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25784?source=see_link\">",
"     \"Dry eyes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91121833\">",
"    <span class=\"h2\">",
"     Nephrolithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menopause may increase urinary calcium excretion, an important risk factor for the development of calcium-containing kidney stones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/112\">",
"     112",
"    </a>",
"    ]. However, the magnitude of the increase is still unclear. In contrast, exogenous estrogen therapy may decrease urinary calcium excretion. Although one might anticipate an increased risk of nephrolithiasis with menopause and a decreased risk with estrogen therapy, data that address this question have been inconsistent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Nurses&rsquo; Health Study, a prospective cohort study, natural menopause was not associated with an increased risk of nephrolithiasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/113\">",
"       113",
"      </a>",
"      ]. In addition, postmenopausal estrogen users, when compared with nonusers, did not have a lower risk of nephrolithiasis.",
"     </li>",
"     <li>",
"      Data from the WHI, the only randomized trial to address this question, suggest that estrogen therapy may",
"      <strong>",
"       increase",
"      </strong>",
"      the risk of nephrolithiasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/114\">",
"       114",
"      </a>",
"      ]. In a post-hoc analysis of the two hormone therapy trials, kidney stone data was obtained by patient self-report. After adjusting for age, body mass index, prior hormone therapy, use of coffee or thiazide diuretics, there was a small excess risk of kidney stones in the hormone groups compared with placebo (39 versus",
"      <span class=\"nowrap\">",
"       34/10,000",
"      </span>",
"      person years; hazard ratio 1.21).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reasons for these discrepant findings are unclear. However, the incidence rates of kidney stones in the WHI were nearly three times higher than in the Nurses&rsquo; Health Study (which included only cases with symptomatic stones) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/113\">",
"     113",
"    </a>",
"    ]. In addition, women taking estrogen were more likely to develop gallstones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/60\">",
"     60",
"    </a>",
"    ], and imaging studies to evaluate the gallbladder would identify asymptomatic kidney stones. Given the small absolute risk reported in this study (five additional cases per 10,000 person years), we do not consider nephrolithiasis to be a major consideration in deciding whether to take short-term hormone therapy for menopausal symptoms (see",
"    <a class=\"local\" href=\"#H438948993\">",
"     'Gallbladder disease'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H439009221\">",
"    <span class=\"h1\">",
"     OTHER ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H822282019\">",
"    <span class=\"h2\">",
"     Weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although women are often concerned that taking postmenopausal hormone therapy will exacerbate the weight gain that occurs in midlife, a meta-analysis of 28 trials in 28,559 women found no evidence of an effect of unopposed oestrogen or combined oestrogen-progestin on body weight or body mass index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H439009228\">",
"    <span class=\"h2\">",
"     Women with primary ovarian insufficiency (premature ovarian failure)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the WHI should not be extrapolated to women with primary ovarian insufficiency (premature ovarian failure; menopause before age 40 years) in whom postmenopausal hormone therapy is generally initiated at a younger age. In otherwise healthy women with primary ovarian insufficiency, we continue their postmenopausal hormone therapy until the average age of menopause, approximately age 50 to 51 years. At that point, the same discussion of potential risks and benefits of postmenopausal hormone therapy should take place. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37880?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\", section on 'Duration of estrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H767061942\">",
"    <span class=\"h2\">",
"     Androgen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of exogenous androgen therapy in peri- and postmenopausal women is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=see_link\">",
"     \"Androgen production and therapy in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34985?source=see_link&amp;anchor=H21#H21\">",
"     \"Sexual dysfunction in women: Management\", section on 'Androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H507776\">",
"    <span class=\"h1\">",
"     EXPERT GROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most expert groups agree that hormone therapy is indicated for the management of menopausal symptoms, but not for the primary or secondary prevention of cardiovascular disease or dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/6,116-118\">",
"     6,116-118",
"    </a>",
"    ]. Some groups suggest that hormone therapy may be reasonable for women with osteoporosis who cannot take non-estrogen therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/23/32122/abstract/4,116\">",
"     4,116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/27/40370?source=see_link\">",
"       \"Patient information: Menopause (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/59/26546?source=see_link\">",
"       \"Patient information: Menopause (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/4/32835?source=see_link\">",
"       \"Patient information: Postmenopausal hormone therapy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/16/32001?source=see_link\">",
"       \"Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7537?source=see_link\">",
"       \"Patient information: Vaginal dryness (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74906167\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For postmenopausal women with moderate-to-severe vasomotor symptoms (and no history of breast cancer or cardiovascular disease), we suggest estrogen-progestin therapy (or unopposed estrogen for those post-hysterectomy) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For women with vaginal atrophy symptoms only, we suggest vaginal estrogen (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40615?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of menopausal symptoms with hormone therapy\", section on 'Patient selection'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of vaginal atrophy\", section on 'Vaginal estrogen therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Postmenopausal hormone therapy is effective for the treatment of menopausal hot flashes and vaginal atrophy caused by hypoestrogenism. However, it is currently not recommended for the prevention of chronic disease such as prevention of cardiovascular or bone disease. (See",
"      <a class=\"local\" href=\"#H91121219\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the Women&rsquo;s Health Initiative (WHI) combined hormone therapy trial, risks included coronary heart disease (CHD) events, stroke, venous thromboembolism (VTE), and breast cancer, while benefits included a reduction of fracture and colorectal cancer risk. Results for stroke, VTE, and fracture risk with unopposed CEE were similar to those in the combined therapy trial. (See",
"      <a class=\"local\" href=\"#H91121219\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast, no increase in either CHD or breast cancer risk was seen with unopposed estrogen use (in fact, a possible reduction in breast cancer risk was observed). The discrepancies in CHD and breast cancer risk between the WHI unopposed estrogen trial and the combined estrogen-progestin trial suggest that the progestin played an important role in the increased CHD and breast cancer risk seen with combined therapy. (See",
"      <a class=\"local\" href=\"#H91121219\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subsequent analyses suggest that the risk of CHD appears to depend upon the timing of exposure, with no excess risk observed in younger menopausal women. In addition, mortality rates appear to be lower in young postmenopausal hormone users compared with nonusers. Thus, for young, symptomatic postmenopausal women, short-term hormone therapy is considered to be a reasonable option (",
"      <a class=\"graphic graphic_figure graphicRef87938 \" href=\"mobipreview.htm?36/2/36911\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link&amp;anchor=H9#H9\">",
"       \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Timing of exposure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of endometrial hyperplasia and other possible risks and benefits of postmenopausal hormone therapy are reviewed above. (See",
"      <a class=\"local\" href=\"#H256690677\">",
"       'Endometrial hyperplasia and carcinoma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H91121403\">",
"       'Other possible benefits'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H35\">",
"       'Other possible risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommendations for postmenopausal hormone therapy use are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40615?source=see_link\">",
"       \"Treatment of menopausal symptoms with hormone therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Estimates of risk for women in their 50s taking five years of hormone therapy are described above. (See",
"      <a class=\"local\" href=\"#H507693\">",
"       'Estimates of risk in women 50 to 59'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/1\">",
"      Taylor HS, Manson JE. Update in hormone therapy use in menopause. J Clin Endocrinol Metab 2011; 96:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/2\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/3\">",
"      Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/4\">",
"      Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012; 7:CD004143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/5\">",
"      Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med 2012; 157:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/6\">",
"      Moyer VA, U.S. Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 158:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/7\">",
"      Rossouw JE, Manson JE, Kaunitz AM, Anderson GL. Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy. Obstet Gynecol 2013; 121:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/8\">",
"      Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95:s1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/9\">",
"      Zhang SM, Manson JE, Rexrode KM, et al. Use of oral conjugated estrogen alone and risk of breast cancer. Am J Epidemiol 2007; 165:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/10\">",
"      Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003; 348:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/11\">",
"      Col NF, Pauker SG. The discrepancy between observational studies and randomized trials of menopausal hormone therapy: did expectations shape experience? Ann Intern Med 2003; 139:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/12\">",
"      Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/13\">",
"      Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/14\">",
"      Shufelt CL, Johnson BD, Berga SL, et al. Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Menopause 2011; 18:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/15\">",
"      Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007; 356:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/16\">",
"      Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006; 21:363.",
"     </a>",
"    </li>",
"    <li>",
"     Kronos Early Estrogen Prevention Study file://www.keepstudy.org/news/index.cfm (Accessed on February 28, 2013).",
"    </li>",
"    <li>",
"     Kronos Longevity Research Institute. Press Release - Hormone therapy has many favorable effects in newly menopausal women: Initial findings of the Kronos Early Estrogen Prevention Study (KEEPS), October 2012 file://www.menopause.org/docs/agm/general-release.pdf?sfvrsn=0 (Accessed on February 28, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/19\">",
"      Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345:e6409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/20\">",
"      Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Trial does not change the conclusions of Cochrane review of long term hormone therapy for perimenopausal and postmenopausal women. BMJ 2012; 345:e8141; author reply e8164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/21\">",
"      Rossouw JE, Manson JE, Kaunitz AM, Stefanick ML. Study had insufficient power to investigate safety. BMJ 2012; 345:e8146; author reply e8164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/22\">",
"      Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289:2673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/23\">",
"      Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/24\">",
"      Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/25\">",
"      Salpeter SR, Cheng J, Thabane L, et al. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009; 122:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/26\">",
"      Martin KA, Manson JE. Approach to the patient with menopausal symptoms. J Clin Endocrinol Metab 2008; 93:4567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/27\">",
"      Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289:3243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/28\">",
"      Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/29\">",
"      Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003; 290:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/30\">",
"      Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998; 92:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/31\">",
"      Zhou B, Sun Q, Cong R, et al. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 2008; 108:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/32\">",
"      Kotsopoulos J, Lubinski J, Neuhausen SL, et al. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 2006; 100:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/33\">",
"      Beral V, Bull D, Reeves G, Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/34\">",
"      Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 1994; 170:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/35\">",
"      Schiff I, Sela HK, Cramer D, et al. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril 1982; 37:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/36\">",
"      Henderson BE. The cancer question: an overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol 1989; 161:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/37\">",
"      Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989; 298:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/38\">",
"      Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/39\">",
"      Strom BL, Schinnar R, Weber AL, et al. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol 2006; 164:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/40\">",
"      Shapiro S, Kelly JP, Rosenberg L, et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985; 313:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/41\">",
"      Chu J, Schweid AI, Weiss NS. Survival among women with endometrial cancer: a comparison of estrogen users and nonusers. Am J Obstet Gynecol 1982; 143:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/42\">",
"      Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med 1997; 157:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/43\">",
"      Johnson SR, Ettinger B, Macer JL, et al. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol 2005; 105:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/44\">",
"      Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/45\">",
"      Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996; 275:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/46\">",
"      Lacey JV Jr, Leitzmann MF, Chang SC, et al. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. Cancer 2007; 109:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/47\">",
"      Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997; 89:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/48\">",
"      Cerin A, Heldaas K, Moeller B. Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy. The Scandinavian LongCycle Study Group. N Engl J Med 1996; 334:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/49\">",
"      Whitehead MI, Fraser D. The effects of estrogens and progestogens on the endometrium. Modern approach to treatment. Obstet Gynecol Clin North Am 1987; 14:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/50\">",
"      Whitehead MI, Hillard TC, Crook D. The role and use of progestogens. Obstet Gynecol 1990; 75:59S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/51\">",
"      Jaakkola S, Lyytinen H, Pukkala E, Ylikorkala O. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol 2009; 114:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/52\">",
"      Weinstein L, Bewtra C, Gallagher JC. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol 1990; 162:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/53\">",
"      Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994; 83:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/54\">",
"      Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986; 67:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/55\">",
"      Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995; 273:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/56\">",
"      Ettinger B, Selby J, Citron JT, et al. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994; 83:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/57\">",
"      Hirvonen E, Salmi T, Puolakka J, et al. Can progestin be limited to every third month only in postmenopausal women taking estrogen? Maturitas 1995; 21:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/58\">",
"      Pickar JH, Yeh IT, Wheeler JE, et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 2003; 80:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/59\">",
"      Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/60\">",
"      Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA 2005; 293:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/61\">",
"      Simon JA, Hunninghake DB, Agarwal SK, et al. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2001; 135:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/62\">",
"      Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/63\">",
"      Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/64\">",
"      Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004; 47:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/65\">",
"      Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993; 329:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/66\">",
"      Cardozo L, Lose G, McClish D, et al. A systematic review of estrogens for recurrent urinary tract infections: third report of the hormones and urogenital therapy (HUT) committee. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/67\">",
"      Brown JS, Vittinghoff E, Kanaya AM, et al. Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. Obstet Gynecol 2001; 98:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/68\">",
"      Stamm WE. Estrogens and urinary-tract infection. J Infect Dis 2007; 195:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/69\">",
"      MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 2001; 4:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/70\">",
"      Col NF, Weber G, Stiggelbout A, et al. Short-term menopausal hormone therapy for symptom relief: an updated decision model. Arch Intern Med 2004; 164:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/71\">",
"      Hlatky MA, Boothroyd D, Vittinghoff E, et al. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002; 287:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/72\">",
"      Rexrode KM, Manson JE. Postmenopausal hormone therapy and quality of life: no cause for celebration. JAMA 2002; 287:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/73\">",
"      Greenspan SL, Resnick NM, Parker RA. The effect of hormone replacement on physical performance in community-dwelling elderly women. Am J Med 2005; 118:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/74\">",
"      Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/75\">",
"      Brunner RL, Gass M, Aragaki A, et al. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. Arch Intern Med 2005; 165:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/76\">",
"      Ekblad S, Bergendahl A, Enler P, et al. Disturbances in postural balance are common in postmenopausal women with vasomotor symptoms. Climacteric 2000; 3:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/77\">",
"      Crilly RG, Delaquerri&egrave;re Richardson L, Roth JH, et al. Postural stability and Colles' fracture. Age Ageing 1987; 16:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/78\">",
"      Hammar ML, Lindgren R, Berg GE, et al. Effects of hormonal replacement therapy on the postural balance among postmenopausal women. Obstet Gynecol 1996; 88:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/79\">",
"      Seeley DG, Cauley JA, Grady D, et al. Is postmenopausal estrogen therapy associated with neuromuscular function or falling in elderly women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 1995; 155:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/80\">",
"      Armstrong AL, Oborne J, Coupland CA, et al. Effects of hormone replacement therapy on muscle performance and balance in post-menopausal women. Clin Sci (Lond) 1996; 91:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/81\">",
"      Brincat M, Versi E, Moniz CF, et al. Skin collagen changes in postmenopausal women receiving different regimens of estrogen therapy. Obstet Gynecol 1987; 70:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/82\">",
"      Holland EF, Studd JW, Mansell JP, et al. Changes in collagen composition and cross-links in bone and skin of osteoporotic postmenopausal women treated with percutaneous estradiol implants. Obstet Gynecol 1994; 83:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/83\">",
"      Maheux R, Naud F, Rioux M, et al. A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994; 170:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/84\">",
"      Ashcroft GS, Dodsworth J, van Boxtel E, et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nat Med 1997; 3:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/85\">",
"      Wolff EF, Narayan D, Taylor HS. Long-term effects of hormone therapy on skin rigidity and wrinkles. Fertil Steril 2005; 84:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/86\">",
"      Sator PG, Sator MO, Schmidt JB, et al. A prospective, randomized, double-blind, placebo-controlled study on the influence of a hormone replacement therapy on skin aging in postmenopausal women. Climacteric 2007; 10:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/87\">",
"      Phillips TJ, Symons J, Menon S, HT Study Group. Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women. J Am Acad Dermatol 2008; 59:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/88\">",
"      Koomen ER, Joosse A, Herings RM, et al. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study. Ann Oncol 2009; 20:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/89\">",
"      Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women: ovulatory life, menopause, and use of exogenous estrogens. Cancer Epidemiol Biomarkers Prev 1994; 3:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/90\">",
"      Tang JY, Spaunhurst KM, Chlebowski RT, et al. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. J Natl Cancer Inst 2011; 103:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/91\">",
"      Nevitt MC, Cummings SR, Lane NE, et al. Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1996; 156:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/92\">",
"      Zhang Y, McAlindon TE, Hannan MT, et al. Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framingham Study. Arthritis Rheum 1998; 41:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/93\">",
"      Cirillo DJ, Wallace RB, Wu L, Yood RA. Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. Arthritis Rheum 2006; 54:3194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/94\">",
"      Paganini-Hill A. The benefits of estrogen replacement therapy on oral health. The Leisure World cohort. Arch Intern Med 1995; 155:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/95\">",
"      Krall EA, Dawson-Hughes B, Hannan MT, et al. Postmenopausal estrogen replacement and tooth retention. Am J Med 1997; 102:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/96\">",
"      Worzala K, Hiller R, Sperduto RD, et al. Postmenopausal estrogen use, type of menopause, and lens opacities: the Framingham studies. Arch Intern Med 2001; 161:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/97\">",
"      Freeman EE, Munoz B, Schein OD, West SK. Hormone replacement therapy and lens opacities: the Salisbury Eye Evaluation project. Arch Ophthalmol 2001; 119:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/98\">",
"      Waetjen LE, Brown JS, Vittinghoff E, et al. The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women. Obstet Gynecol 2005; 106:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/99\">",
"      Troisi RJ, Speizer FE, Willett WC, et al. Menopause, postmenopausal estrogen preparations, and the risk of adult-onset asthma. A prospective cohort study. Am J Respir Crit Care Med 1995; 152:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/100\">",
"      Lieberman D, Kopernik G, Porath A, et al. Sub-clinical worsening of bronchial asthma during estrogen replacement therapy in asthmatic post-menopausal women. Maturitas 1995; 21:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/101\">",
"      Hepburn MJ, Dooley DP, Morris MJ. The effects of estrogen replacement therapy on airway function in postmenopausal, asthmatic women. Arch Intern Med 2001; 161:2717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/102\">",
"      Meier CR, Sturkenboom MC, Cohen AS, Jick H. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J Rheumatol 1998; 25:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/103\">",
"      S&aacute;nchez-Guerrero J, Liang MH, Karlson EW, et al. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995; 122:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/104\">",
"      Akkad AA, Habiba MA, Ismail N, et al. Abnormal uterine bleeding on hormone replacement: the importance of intrauterine structural abnormalities. Obstet Gynecol 1995; 86:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/105\">",
"      Sener AB, Se&ccedil;kin NC, Ozmen S, et al. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil Steril 1996; 65:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/106\">",
"      Polatti F, Viazzo F, Colleoni R, Nappi RE. Uterine myoma in postmenopause: a comparison between two therapeutic schedules of HRT. Maturitas 2000; 37:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/107\">",
"      Palomba S, Sena T, Noia R, et al. Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas. Obstet Gynecol 2001; 98:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/108\">",
"      Ang WC, Farrell E, Vollenhoven B. Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review. Climacteric 2001; 4:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/109\">",
"      Yang CH, Lee JN, Hsu SC, et al. Effect of hormone replacement therapy on uterine fibroids in postmenopausal women--a 3-year study. Maturitas 2002; 43:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/110\">",
"      Harden CL, Pulver MC, Ravdin L, Jacobs AR. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia 1999; 40:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/111\">",
"      Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA 2001; 286:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/112\">",
"      Nordin BE, Need AG, Morris HA, et al. Evidence for a renal calcium leak in postmenopausal women. J Clin Endocrinol Metab 1991; 72:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/113\">",
"      Mattix Kramer HJ, Grodstein F, Stampfer MJ, Curhan GC. Menopause and postmenopausal hormone use and risk of incident kidney stones. J Am Soc Nephrol 2003; 14:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/114\">",
"      Maalouf NM, Sato AH, Welch BJ, et al. Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials. Arch Intern Med 2010; 170:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/115\">",
"      Norman RJ, Flight IH, Rees MC. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Cochrane Database Syst Rev 2000; :CD001018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/116\">",
"      North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012; 19:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/117\">",
"      Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation 2011; 123:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/23/32122/abstract/118\">",
"      American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease. Obstet Gynecol 2008; 112:1189.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7427 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-2EE9D05621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_23_32122=[""].join("\n");
var outline_f31_23_32122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H74906167\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91121219\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H507693\">",
"      ESTIMATES OF RISK IN WOMEN 50 TO 59",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H507700\">",
"      Benefit or no effect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H507707\">",
"      Risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H178089454\">",
"      CARDIOVASCULAR EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178089461\">",
"      Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Younger postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91122874\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H256689819\">",
"      CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H256689856\">",
"      Ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H256690677\">",
"      Endometrial hyperplasia and carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H256690730\">",
"      - Protective effect of progestins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H256690737\">",
"      - Endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H256690015\">",
"      Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H438948986\">",
"      COGNITIVE FUNCTION AND DEMENTIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H438948993\">",
"      GALLBLADDER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H256689942\">",
"      OSTEOPOROTIC FRACTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TYPE 2 DIABETES MELLITUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91121403\">",
"      OTHER POSSIBLE BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Recurrent urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Health-related quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Falls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      OTHER POSSIBLE RISKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Bronchospasm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Uterine leiomyomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Dry eye syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91121833\">",
"      Nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H439009221\">",
"      OTHER ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H822282019\">",
"      Weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H439009228\">",
"      Women with primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H767061942\">",
"      Androgen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H507776\">",
"      EXPERT GROUPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74906167\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7427\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7427|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/2/36911\" title=\"figure 1\">",
"      Risks and benefits of MHT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/11/14525\" title=\"figure 2\">",
"      HRT and colorectal CA WHI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/44/16077\" title=\"figure 3\">",
"      HRT and hip fracture WHI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/31/20989\" title=\"figure 4\">",
"      ERT minimizes recurrent UTI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/45/20184?source=related_link\">",
"      Androgen production and therapy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=related_link\">",
"      Classification and diagnosis of endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/34/40486?source=related_link\">",
"      Continuous postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25784?source=related_link\">",
"      Dry eyes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7336?source=related_link\">",
"      Endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/43/37562?source=related_link\">",
"      Epidemiology and pathogenesis of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4489?source=related_link\">",
"      Epidemiology of and risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41975?source=related_link\">",
"      Estrogen and cognitive function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37880?source=related_link\">",
"      Management of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16646?source=related_link\">",
"      Menstrual function, menopause, and hormonal contraceptives in women with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/59/26546?source=related_link\">",
"      Patient information: Menopause (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/27/40370?source=related_link\">",
"      Patient information: Menopause (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/16/32001?source=related_link\">",
"      Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/4/32835?source=related_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7537?source=related_link\">",
"      Patient information: Vaginal dryness (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17831?source=related_link\">",
"      Postmenopausal hormone therapy in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5514?source=related_link\">",
"      Recurrent urinary tract infection in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34985?source=related_link\">",
"      Sexual dysfunction in women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40615?source=related_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6954?source=related_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10072?source=related_link\">",
"      Women and lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_23_32123="TEN SCORTEN criteria";
var content_f31_23_32123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    SCORTEN schema",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       Independent prognosis factors",
"      </td>",
"      <td class=\"subtitle1\">",
"       Weight",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Age",
"      </td>",
"      <td>",
"       &ge; 40 years",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Malignancy*",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Body surface area detached",
"      </td>",
"      <td>",
"       &ge; 10%",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tachycardia",
"      </td>",
"      <td>",
"       &ge; 120/min",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serum urea",
"      </td>",
"      <td>",
"       &gt; 10 mmol/l",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serum glucose",
"      </td>",
"      <td>",
"       &gt; 14 mmol/l",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serum bicarbonate",
"      </td>",
"      <td>",
"       &lt; 20 mmol/l",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       <strong>",
"        SCORTEN#",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        7",
"       </strong>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Malignancy: evolving cancer and haematological malignancies.",
"     <br>",
"      &bull; SCORTEN represents the number of abnormal variables among the seven independent prognosis factors (a weight of 1 was assigned to each independent variable).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Gu&eacute;gan, S, Bastuji-Garin, S, Poszepczynska-Guign&eacute;, E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126:272 Copyright &copy; Macmillan Publishers Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_23_32123=[""].join("\n");
var outline_f31_23_32123=null;
var title_f31_23_32124="ESC risk stratification LQTS";
var content_f31_23_32124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    European Society of Cardiology recommendations for risk stratification for sudden cardiac death: Long QT syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syncope",
"       </td>",
"       <td>",
"        Class I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TdP/VF/CA",
"       </td>",
"       <td>",
"        Class I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        JLN recessive variant",
"       </td>",
"       <td>",
"        Class I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LQT3 genetic variant",
"       </td>",
"       <td>",
"        Class I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        QTc &gt;600 msec",
"       </td>",
"       <td>",
"        Class IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac events in infants",
"       </td>",
"       <td>",
"        Class IIa*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postpartum period",
"       </td>",
"       <td>",
"        Class IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female gender",
"       </td>",
"       <td>",
"        Class IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syndactyly and AV block",
"       </td>",
"       <td>",
"        Class IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T wave alternans (macroscopic)",
"       </td>",
"       <td>",
"        Class IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history",
"       </td>",
"       <td>",
"        Class IIb*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        QT dispersion",
"       </td>",
"       <td>",
"        Class IIb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Programmed electrical stimulation",
"       </td>",
"       <td>",
"        Class III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class I:",
"        </strong>",
"        Conditions for which there is evidence and/or",
"general agreement that a given procedure or treatment is",
"useful and effective.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class II:",
"        </strong>",
"        Conditions for which there is conflicting",
"evidence and/or a divergence of opinion about the",
"usefulness/efficacy of a procedure or treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class IIa:",
"        </strong>",
"        Weight of evidence/opinion is in favor of",
"usefulness/efficacy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class",
"IIb:",
"        </strong>",
"        Usefulness/efficacy less well established by",
"evidence/opinion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class",
"III:",
"        </strong>",
"        Conditions for which there is evidence and/or",
"general agreement that the procedure/treatment is not useful and in",
"some cases may be harmful.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TdP: torsade de pointes; VF: ventricular fibrillation; CA: cardiac arrest; JNL: Jervell and Lange Nielsen; LQT: long QT; QTc: correct QT interval; AV: atrioventricular.",
"     <br/>",
"     * Opinion of task force panel.",
"    </div>",
"    <div class=\"reference\">",
"     Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Eur Heart J 2001; 22:1374.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_23_32124=[""].join("\n");
var outline_f31_23_32124=null;
var title_f31_23_32125="AGEP inducing drugs 2";
var content_f31_23_32125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Non-antimicrobial drugs reported as cause of acute generalized exanthematous pustulosis (AGEP)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Acarbose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acetylsalicylic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allopurinol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allylisopropylacetylurea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoxapine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azathioprine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bamiphylline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boldoflorine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buphenine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bufexamac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium channel blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbimazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbutamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Celecoxib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemotherapy (high dose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chromium picolinate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cimetidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clemastine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clobazam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clopidogrel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clozapine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contrast media",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corticosteroids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytarabine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dalteparin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dextropropoxyphene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disulfiram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Docetaxe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enalapril",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eperisone hydrochloride",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epoetin alpha",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eprazinon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etoricoxib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etodolac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fenoterol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluindione",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Furosemide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gefitinib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herbal medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrochlorothiazide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ibuprofen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Icodextrin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Illicit street drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imatinib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isotretinoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laquer chicken",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meladinine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mercury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metamizole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methylphenidate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Milk Thistle Tea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morphine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nadoxolol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nifedipine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nimesulide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Omeprazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paracetamol (acetaminophen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pemetrexed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Piperazine ethionamate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propaphenone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostaglandin E1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudoephedrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PUVA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quinidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ranibizumab (intravitreal)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ranitidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhus (lacquer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sennoside",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sertraline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simvastatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spider bites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulbutiamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfasalazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teicoplanin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Terazosin hydrochloride",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tetrazepam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thalidomide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thallium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ticlopidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topical agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vaccines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valdecoxib",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_23_32125=[""].join("\n");
var outline_f31_23_32125=null;
var title_f31_23_32126="Early surgery flail MV";
var content_f31_23_32126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Early surgery for flail mitral leaflet improves outcome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 401px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Early surgery for flail mitral leaflet improves outcomes as compared to conservative therapy. Among 221 with mitral regurgitation due to a flail leaflet who were eligible for surgery, 63 underwent early mitral valve surgery while 158 were treated medically. Compared to medical therapy, early surgery was associated with a higher overall survival (p = 0.028), lower cardiac mortality (p = 0.025), a lower incidence of atrial fibrillation (p = 0.032), and a lower incidence of heart failure (p = 0.046).",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Ling LH, Enriquez-Sarano M, Seward JB, et al. Circulation 1997; 96:1819.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_23_32126=[""].join("\n");
var outline_f31_23_32126=null;
var title_f31_23_32127="Radial head subluxation classic arm position";
var content_f31_23_32127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Classic arm position in children with radial head subluxation (nursemaid's elbow)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Children with radial head subluxation typically hold the affected arm close to the body with the elbow slightly flexed or extended and the forearm pronated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_23_32127=[""].join("\n");
var outline_f31_23_32127=null;
